EP0751943A1 - Triazole compounds and processes for the preparation thereof - Google Patents

Triazole compounds and processes for the preparation thereof

Info

Publication number
EP0751943A1
EP0751943A1 EP95912490A EP95912490A EP0751943A1 EP 0751943 A1 EP0751943 A1 EP 0751943A1 EP 95912490 A EP95912490 A EP 95912490A EP 95912490 A EP95912490 A EP 95912490A EP 0751943 A1 EP0751943 A1 EP 0751943A1
Authority
EP
European Patent Office
Prior art keywords
triazol
butanol
thio
thiadiazol
difluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP95912490A
Other languages
German (de)
French (fr)
Inventor
Jong Wook Lee
Jeong Seok Chae
Heui Il Kang
Chun Ho Lee
Soo Bong Park
Won Hui Yi
Chul 103-1509 Woncheon Jukong Apart. Kim
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yuhan Corp
Original Assignee
Yuhan Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1019940004918A external-priority patent/KR950026875A/en
Priority claimed from KR1019940004917A external-priority patent/KR950026874A/en
Priority claimed from KR1019940012285A external-priority patent/KR960000880A/en
Application filed by Yuhan Corp filed Critical Yuhan Corp
Publication of EP0751943A1 publication Critical patent/EP0751943A1/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles

Definitions

  • the present invention relates to novel triazole compounds with an antifungal activity, processes for the preparation of these compounds, and pharmaceutical compositions containing same as active ingredients.
  • A represents an alkyl substituted sulfone (-S0 2 -), sulfoxy (-SO-) or sulfide (-S-) group,
  • EP Nos . 47338 and 100193 disclose the compounds of the above formula wherein A represents a substituted methylthio group (-S-CH 2 -).
  • A represents a disulfide group(-S-SO n -)
  • a compound wherein A represents -S-C- or -S-SO n - group are provided in JP 3-258764 and EP 0421210, respectively.
  • a compound having a substituted thio group EP 0061835, EP 0095828 and EP 0552974
  • a dithiocarbamate group EP 0446877
  • X and Y are independently a hydrogen or halogen
  • R is a group selected from the formulae consisting of (I-a),
  • R 1 represents a C._ A alkoxy, C._ ⁇ alkoxymethyl, C._ ⁇ alkylthio, C,_ A alkylthiomethyl, amino, C._ 4 alkylamino group which may form a ring with a nitrogen atom, or an optionally substituted C_._ A alkyl, styryl, phenyl or heteroaryl group;
  • R 2 represents a hydrogen or a C 1 _ 3 alkyl, phenyl, substituted phenyl, morpholinyl, pyrrolidinyl, thiomorpholinyl or piperidinyl group; and
  • R 3 represents a hydrogen or halogen or a C*_ 3 alkyl, C._ 3 alkoxy or nitro group.
  • the triazole compounds of formula (I) of the present invention are characterized by a pentagonal or fused heterocyclic ring coupled to a sulfur atom as a substituent in 3-position.
  • the compounds of formula (I-A) wherein Z is a nitrogen are those of formula (I) wherein R is a 1,2,4-thiadiazol group, and the compounds of formula (I-A) wherein Z is a carbon are those of formula (I) wherein R is a thiazol group.
  • preferred compounds of the present invention are those of formula(I) wherein R is a 1 , 2, 3-thiadiazol group, i.e., the compounds having the following formula(I- C): wherein X, Y and R 2 are the same as defined in formula(I). Representative compounds thereof are shown in Table 3 below.
  • triazole compounds of the present invention include those of formula(I) wherein R is a fused heterocyclic ring selected from (I-d) to (I-j), i.e., the compounds having the following formulae (I-D) to (I-J):
  • the triazole compounds of formula(I) of the present invention include two asymmetric carbons in 2 and 3 positions; and, therefore, the present invention encompasses, within its scope, racemic mixtures of (2R*,3R*) form and an enantiomer of (2R,3R) form, as well as each diastereomers, which can be collectively represented by the formula (I) .
  • Suitable pharmacologically acceptable salts of the triazole compounds(I) may include salts of inorganic and organic acids, such as hydrochloride, nitrate, oxalate and methanesulfonate; and, in addition, other salts known in the art.
  • Such pharmacologically acceptable salts of the compounds of formula(I) may be prepared by a conventional method.
  • the triazole compounds( I ) of the present invention may be prepared in accordance with the following methods.
  • the triazole compounds of formula(I) of the present invention may be prepared by reacting a compound of formula(II) with a compound of formula(III) or its an alkali metal salt in the presence of lithium perchlorate (LiC10 A ) .
  • the compound of formula(II) used in the present invention may be prepared, e.g., in accordance with the procedures described in EP Patent No. 421210.
  • the compound of formula(III) may be prepared by methods disclosed in various references, e.g., in accordance with the procedures described in Adv. Heterocycl. Che . , 5_, 119 (1965) for the compound of formula(Ill-a) ; J. Heterocycl. Chem. , 15 , 1295 (1978) for the compound of formula(III-c) ; and Adv. Heterocycl. Chem., 14, 43 (1972) and J. Org. Chem. , 47 , 5255 (1982) for the compounds of formulae (Ill-d) to (III-j); or, alternatively, by reacting a corresponding isothiazol-3-thione derivatives with a thiol.
  • R 1 , R 2 and R 3 are the same as defined previously and M represents an alkali metal.
  • the compound( II ) , the compound( III ) and LiC10 ⁇ are preferably employed in a molar ratio of 1 : 1 to 5 : 1 to 5, more preferably 1 : 1 to 2 : 1 to 2.
  • the above reaction may be conducted in an organic polar solvent such as methanol, acetonitrile, dimethylformamide and the like, at a temperature ranging from 50 to 130 °C, preferably from 80 to 110 °C, for a period ranging from 4 to 18 hours, preferably from 4 to 10 hours.
  • an organic polar solvent such as methanol, acetonitrile, dimethylformamide and the like
  • the triazole compounds of formula(I) of the present invention may be prepared by reacting a compound of formula(IV) with a compound of formula(V) in the presence of a base.
  • the compound of formula(IV) may be prepared, e.g., in accordance with the procedures described in EP Patent No. 421210.
  • the compound of formula(V) may be prepared by methods disclosed in various references, e.g., in accordance with the procedures described in Adv. Heterocycl. Chem., 5_, 119 (1965) for the compound of formula (V-a); and Adv. Heterocycl. Chem. , 14, 43 (1972), J. Orq. Chem., 45 , 617 (1980), Aust. J. Chem. , 24, 2405 (1971), Can. J. Chem. , 51, 1741 (1973), and Chem.
  • the base which may be used in the above reaction includes an inorganic base such as sodium hydride (NaH), potassium carbonate (K 2 C0 3 ) or sodium methoxide (MeONa), and an organic base such as triethylamine or 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) .
  • an inorganic base such as sodium hydride (NaH), potassium carbonate (K 2 C0 3 ) or sodium methoxide (MeONa)
  • an organic base such as triethylamine or 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) .
  • the above reaction may be conducted in an organic polar solvent such as methanol, acetonitrile, dimethoxyethane, dimethylformamide and the like, at a temperature ranging from 0 to 25 °C, preferably from 0 to 5 °C, for a period ranging from 15 minutes to 2 hours, preferably from 15 to 30 minutes .
  • the present invention also provides pharmaceutical compositions containing the compounds of formula(I) and pharmacologically acceptable salts thereof as active ingredients, in association with pharmaceutically acceptable carriers, excipients or other additives, if necessary.
  • the pharmaceutical compositions of the present invention may be administered orally or by injection.
  • the pharmaceutical composition for oral administration may take various forms such as tablets, granules, solutions and gelatin capsules, which may contain conventional additives such as a diluent, lubricant, absorbent, colorant, favour, sweetener and the like.
  • the composition for injection may be an isotonic solution or a suspension, and may be sterilized and/or contain an adjuvant such as a preservative, stabilizer, wetting agent, emulsifier, a salt for controlling an osmotic pressure and/or a buffer solution, and other pharmaceutically effective materials.
  • the pharmaceutical composition may be administered for the treatment of fungal infections in a dosage ranging from 0.05 to 10 mg/kg/day, more preferably from 1.0 to 5 mg/kg/day, depending on the routes and frequency of administration, although the dosage may vary in accordance with the kind and severity of the disease.
  • a dosage ranging from 0.05 to 10 mg/kg/day, more preferably from 1.0 to 5 mg/kg/day, depending on the routes and frequency of administration, although the dosage may vary in accordance with the kind and severity of the disease.
  • the following Examples are given for the purpose of illustration only and are not intended to limit the scope of the invention.
  • the reaction mixture was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1).
  • the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography and recrystallized from isopropyl ether/n-hexane to afford the title compound.
  • reaction mixture was evaporated under reduced pressure, diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1).
  • the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography to afford the title compound. M.p.
  • Example 20 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-(2,2,3, 3-tetrafluoropropoxy ) styryl)-l,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
  • Example 22 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-phenoxymethyl-l,2,4-thiadiazol-5-yl)thio-1-( 1H-1,2, 4- triazol-l-yl)-2-butanol HCl
  • the same procedures as in Example 3 above were repeated using 0.680 g (0.003 mol) of 5-chloro-3-phenoxymethyl-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole and then the resulting product was recrystallized from ethylether by the addition of 5 ml of HCl-saturated ethyl ether to afford the title compound.
  • M.p. 143 to 146 °C
  • Example 25 Synthesis of ( 2R , 3R ) -2- ( 2 , 4-dif luorophenyl ) - 3- [ 3- ( 4-f luorophenyl ) - 1 , 2 , 4-thiadiazol-5 -yl ] thio- 1 - ( 1H- 1 , 2 , 4-triazol-l-yl ) -2-butanol
  • the same procedures as in Example 1 above were repeated using 0.637 g (0.003 mol) of 3-(4-£luorophenyl)-1, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound.
  • Example 28 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-phenyl-l ,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
  • the same procedures as in Example 1 above were repeated using 0.583 g (0.003 mol) of 3-phenyl-l,2,4-thiadiazol-5- thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound.
  • M.p. 135 to 138 °C
  • Example 30 Synthesis of ( 2R* , 3R* ) -2- ( 2 , 4-dif luorophenyl ) - 3 - [ 3 - ( 4-pyridyl ) -1 , 2 , -thiadiazol-5-yl ] thio- 1- ( 1H- 1 , 2 , 4- triazol-1-yl ) -2-butanol
  • Example 31 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 4- ( 1-(N-hydroxyiminoethyl)phenyl)-1, 2 , 4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
  • the same procedures as in Example 1 above were repeated using 0.754 g (0.003 mol) of 4-(1-(N-hydroxyiminoethyl) phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t-butyl- l,2,4-thiadiazol-5-thiol to afford the title compound.
  • M.p. 177 to 180 °C
  • Example 56 Synthe ⁇ i ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-biphenyl)-l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4- triazol-1-yl)-2-butanol
  • Example 57 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-(2,2,3, 3-tetrafluoropropoxy) phenyl ) -1 , 2 , 4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
  • Example 62 Synthesi ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-methanesulfonylphenyl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
  • Example 64 Synthesi ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2,5-difluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
  • Example 68 Synthe ⁇ is of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3-pyrrol-l-yl)phenyl-l,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
  • Example 72 Synthesis of (2R, 3R)-2-(2,4-difluorophenyl)-3- (3-styryl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
  • the same procedures as in Example 3 above were repeated using 0.571 g (0.002 mol) of (2R, 3R)-2-(2,4- difluorophenyl)-3-mercapto-l- (lH-l,2,4-triazol-l-yl)-2- butanol and 0.668 g (0.003 mol) of 5-chloro-3-styryl-l, 2,4- thiadiazole in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- mercapto-l-(lH-l,2,4-triazol-l-yl)-2-butanol and 5-chloro-3-
  • Example 78 Synthe ⁇ i ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(2,4-dichlorophenyl)-thiazol-2-yl]thio-1-(1H-1 ,2,4- triazol-1-yl)-2-butanol
  • Example 80 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(4-ethylthiazol-2-yl)thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol- oxalate
  • Example 2 The same procedures as in Example 1 above were repeated using 0.436 g (0.003 mol) of 4-ethylthiazol-2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol and to the compound thus obtained was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound.
  • Example 84 Synthe ⁇ i ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4- (2, 3-dichlorostyryl)-thiazol-2-yl]thio-1-(1H-1, 2,4- triazol-1-yl)-2-butanol
  • Example 85 Synthesi ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(1,2, 3-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol
  • the reaction mixture was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1).
  • the organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which wa ⁇ purified by ⁇ ilica gel column chromatography to afford the title compound.
  • Example 88 Synthe ⁇ is of (2R*, 3R* ) -2- (2, 4-dif luorophenyl )- 3- ( 4-methyl-l , 2 , 3-thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol- l-yl)-2-butanol
  • Example 85 The same procedures as in Example 85 above were repeated using 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.753 g (0.003 mol) of 4-(2,4- difluorophenyl)-1,2,3-thiadiazol-5-thiol-Na ⁇ alt, and thereto was added 0.19 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound.
  • reaction mixture wa ⁇ diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography and recrystallized from isopropyl ether to afford the title compound. M.p. : 155 to 158 °C
  • the re ⁇ ulting mixture was stirred for 1 hour and evaporated to obtain a concentrate, which was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography to afford the title compound.
  • Example 100 Synthesi ⁇ of (2R*, 3R*)-2-(4-fluorophenyl)-3- (1,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol oxalate
  • Example 103 Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(5, 6-dimethoxy-l,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
  • Example 105 Synthesi ⁇ of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(7-chloro-l, 2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
  • Example 109 Synthesi ⁇ of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-(2, l-benzoisothiazol-3-yl)thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
  • Example 110 Synthe ⁇ is of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(5-nitro-2,l-benzoi ⁇ othiazol-3-yl)thio-l-(lH-l,2,4- triazol-1-yl)-2-butanol
  • Example 113 Synthesi ⁇ of (2R, 3R)-2-(2,4-difluorophenyl)- 3-(thieno[3,4-d]isothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
  • mice Male ICR mice (22 to 25 g) were divided into 48 groups, each consisting of ten mice. The first was a control group employing no te ⁇ t compound, the second was a comparative group employing Fluconazole, a commercially available triazolic antifungal agent, and the 3rd to 48th were employed the compounds of the present invention.
  • Candida albicans B02630 wa ⁇ cultured in SDA medium for 24 hours, and then su ⁇ pended in a sterilized saline in a concentration of 4.0 x 10 7 CFU/ml. All the test animals were infected by injecting 0.2 ml of the fungi ⁇ u ⁇ pension into tail vein.
  • Fluconazole and the inventive compound ⁇ dis ⁇ olved in polyethylene glycol 200 were admini ⁇ tered orally in an amount of 2 mg/kg into the second group and the 3rd-48th group, respectively.
  • the test compounds were administered three times at an interval of 24 hours. The number of the mice survived was counted at 24 hour interval and the results are shown in Table 5.
  • mice Male ICR mice (22 to 25 g) of 36 group ⁇ , each group consisting of eight mice, were infected by Candida albicans in accordance with the same procedures a ⁇ de ⁇ cribed previou ⁇ ly.
  • the inventive compound prepared in Example 5 of the pre ⁇ ent invention
  • polyethylene glycol 200 was administered orally in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg into the 2nd-6th group five ti e ⁇ at an interval of 24 hours. No compound was administered into the first group.
  • the inventive compounds prepared in Example 47, 72, 73, 93, 97 and 98 were also administered orally into the remaining 7th- 36th groups in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg. The number of the mice survived was counted at 24 hour interval.
  • mice Male ICR mice (22 to 25 g) were divided into 36 group ⁇ , each group con ⁇ isting of eight mice.
  • Cryptococcus neoformans IFM 40092 was cultured in SDA medium for 24 hours, and then suspended in a sterilized ⁇ aline in a concentration of 2.0 x 10 8 CFU/ml.
  • cyclophosphamide as a immunosuppressive agent was administered intraperitoneally in an amount of 2 mg/mouse. 24 hour ⁇ after the administration, each group was infected by injecting into tail vein 0.2 ml of the fungi suspension.
  • Example 5 2 hours after the infection, the inventive compounds prepared in Example 5, 47, 72, 73, 93, 97 and 98 of the present invention were administered into the the test animals in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg as described previously The ED 50 values measured are shown in Table 6.
  • mice Male ICR mice (22 to 25 g) were divided into 36 groups, each group consisting of eight mice. To each group cyclophosphamide (immuno ⁇ uppres ⁇ ive agent) was administered intraperitoneally in an amount of 2 mg/mouse. 24 hours after the administration, each group was infected by injecting into tail vein 0.2 ml of a suspension of Asperqillus fumi ⁇ atus 3319119 spore (2.0 x 10 6 CFU/ml in a sterilized saline) .
  • cyclophosphamide immuno ⁇ uppres ⁇ ive agent
  • the inventive compounds prepared in Example 5, 47, 72, 73, 93, 97 and 98 of the present invention were administered into the the test animals in each amount of 100, 50, 25, 12.5 and 6.25 mg/kg as described previously.
  • the ED 50 values measured are shown in Table 6.
  • the compounds of formula(I) and their pharmacologically acceptable salts of the present invention have a potent antifungal activity against variou ⁇ fungi, e.g., Candida albican ⁇ , Cryptococcus neoformans, and Asperqillus fumigatu ⁇ and, therefore, can be used for the treatment of fungal infections in mammals including human beings.
  • variou ⁇ fungi e.g., Candida albican ⁇ , Cryptococcus neoformans, and Asperqillus fumigatu ⁇

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Novel triazole compounds of formula (I), and pharmacologically acceptable salts thereof, possess potent antifungal activities, and are useful for the treatment of fungal infections.

Description

TRIAZOLE COMPOUNDS AND PROCESSES FOR THE PREPARATION THEREOF
Field of the Invention
The present invention relates to novel triazole compounds with an antifungal activity, processes for the preparation of these compounds, and pharmaceutical compositions containing same as active ingredients.
Description of the Prior Art
Hitherto many studies have been made to develop various compounds having an antifungal activity for the treatment of fungal infections in mammals including human beings. Recently, triazole derivatives with a low toxicity for an oral administration, such as Fluconazole (GB 2099818) and Itraconazole (USP 4,276,179), have been reported.
As a known antifungal agent, triazole derivatives of the following formula have been published in EP 0322800 Al and EP 0178533:
' TOH
wherein A represents an alkyl substituted sulfone (-S02-), sulfoxy (-SO-) or sulfide (-S-) group,
Further, EP Nos . 47338 and 100193 disclose the compounds of the above formula wherein A represents a substituted methylthio group (-S-CH2-). Similarly, a compound wherein A is a disulfide group(-S-SOn-) and a compound wherein A represents -S-C- or -S-SOn- group are provided in JP 3-258764 and EP 0421210, respectively. Also disclosed is a compound having a substituted thio group (EP 0061835, EP 0095828 and EP 0552974) or a dithiocarbamate group (EP 0446877) as the group A. However, there has continued to exist a need to develop more effective compounds with a superior antifungal activity and a lower toxicity. Summary of the Invention
Accordingly, it is a primary object of the present invention to provide novel triazole compounds having an excellent antifungal activity.
It is another object of the present invention to provide pharmaceutical compositions containing the same.
It is a further object of the present invention to provide processes for the preparation of said novel compounds .
In accordance with one aspect of the present invention, there are provided novel triazole compound of formula ( I ) and pharmacologically acceptable salts thereof:
wherein,
X and Y are independently a hydrogen or halogen; and
R is a group selected from the formulae consisting of (I-a),
(I-b), (I-c), (I-d), (1-e), (i-f), (I-g), (I-h), (I-i) and
(I-a) (I-b) (I-c)
(I-g) (I-h) (I-i) (I-j) wherein Z is a nitrogen or carbon; R1 represents a C._A alkoxy, C._Λ alkoxymethyl, C._Λ alkylthio, C,_A alkylthiomethyl, amino, C._4 alkylamino group which may form a ring with a nitrogen atom, or an optionally substituted C_._ A alkyl, styryl, phenyl or heteroaryl group; R2 represents a hydrogen or a C1_3 alkyl, phenyl, substituted phenyl, morpholinyl, pyrrolidinyl, thiomorpholinyl or piperidinyl group; and R3 represents a hydrogen or halogen or a C*_3 alkyl, C._3 alkoxy or nitro group.
Detailed Description of the Invention
The triazole compounds of formula (I) of the present invention are characterized by a pentagonal or fused heterocyclic ring coupled to a sulfur atom as a substituent in 3-position.
Among the compounds of formula (I), preferred are the compounds of the following formula (I-A)
wherein X, Y, Z and „ R1 are the same as defined in formula(I) .
The compounds of formula (I-A) wherein Z is a nitrogen are those of formula (I) wherein R is a 1,2,4-thiadiazol group, and the compounds of formula (I-A) wherein Z is a carbon are those of formula (I) wherein R is a thiazol group.
Representative compounds thereof are shown in Table 1 below. Table 1
Among the compounds of formula(I), also preferred compounds are the compounds (I) wherein R is a 1,2,5- thiadiazol group, i.e., the compounds having the following formula(I-B) :
wherein X, Y and R2 are the same as defined in formula(I). Representative compounds thereof are shown in Table 2 below.
Table 2
Similarly preferred compounds of the present invention are those of formula(I) wherein R is a 1 , 2, 3-thiadiazol group, i.e., the compounds having the following formula(I- C): wherein X, Y and R2 are the same as defined in formula(I). Representative compounds thereof are shown in Table 3 below.
Table 3
Further, the triazole compounds of the present invention include those of formula(I) wherein R is a fused heterocyclic ring selected from (I-d) to (I-j), i.e., the compounds having the following formulae (I-D) to (I-J):
(I-D) (I-E) (I-F)
(I-G) (I-H)
(I-I) (I-J)
wherein X, Y and R3 are the same as defined in formula(I). Representative compounds thereof are shown in Table 4 below.
Table 4
The triazole compounds of formula(I) of the present invention include two asymmetric carbons in 2 and 3 positions; and, therefore, the present invention encompasses, within its scope, racemic mixtures of (2R*,3R*) form and an enantiomer of (2R,3R) form, as well as each diastereomers, which can be collectively represented by the formula (I) .
Furthermore, the present invention embraces, within its scope, those pharmacologically acceptable salts of the compounds of formula(I). Suitable pharmacologically acceptable salts of the triazole compounds(I) may include salts of inorganic and organic acids, such as hydrochloride, nitrate, oxalate and methanesulfonate; and, in addition, other salts known in the art. Such pharmacologically acceptable salts of the compounds of formula(I) may be prepared by a conventional method. The triazole compounds( I ) of the present invention may be prepared in accordance with the following methods.
Method A
The triazole compounds of formula(I) of the present invention may be prepared by reacting a compound of formula(II) with a compound of formula(III) or its an alkali metal salt in the presence of lithium perchlorate (LiC10A) .
(II) (III)
wherein X, Y and R are the same as defined previously.
The compound of formula(II) used in the present invention may be prepared, e.g., in accordance with the procedures described in EP Patent No. 421210.
Further, the compound of formula(III) may be prepared by methods disclosed in various references, e.g., in accordance with the procedures described in Adv. Heterocycl. Che . , 5_, 119 (1965) for the compound of formula(Ill-a) ; J. Heterocycl. Chem. , 15 , 1295 (1978) for the compound of formula(III-c) ; and Adv. Heterocycl. Chem., 14, 43 (1972) and J. Org. Chem. , 47 , 5255 (1982) for the compounds of formulae (Ill-d) to (III-j); or, alternatively, by reacting a corresponding isothiazol-3-thione derivatives with a thiol.
(Ill-a) (III-c)
(in-d) (Ill-e) (Ill-f) (Ill-g)
(Ill-h) (Ill-i) (III-j)
wherein R1, R2 and R3 are the same as defined previously and M represents an alkali metal.
In the above method, the compound( II ) , the compound( III ) and LiC10Λ are preferably employed in a molar ratio of 1 : 1 to 5 : 1 to 5, more preferably 1 : 1 to 2 : 1 to 2.
The above reaction may be conducted in an organic polar solvent such as methanol, acetonitrile, dimethylformamide and the like, at a temperature ranging from 50 to 130 °C, preferably from 80 to 110 °C, for a period ranging from 4 to 18 hours, preferably from 4 to 10 hours.
Method B Alternatively, the triazole compounds of formula(I) of the present invention may be prepared by reacting a compound of formula(IV) with a compound of formula(V) in the presence of a base.
(IV) (V)
wherein X, Y and R are the same as defined previously, and L represents a halogen.
The compound of formula(IV) may be prepared, e.g., in accordance with the procedures described in EP Patent No. 421210.
Further, the compound of formula(V) may be prepared by methods disclosed in various references, e.g., in accordance with the procedures described in Adv. Heterocycl. Chem., 5_, 119 (1965) for the compound of formula (V-a); and Adv. Heterocycl. Chem. , 14, 43 (1972), J. Orq. Chem., 45 , 617 (1980), Aust. J. Chem. , 24, 2405 (1971), Can. J. Chem. , 51, 1741 (1973), and Chem. Ber., 100, 3326 (1967) for the compounds of formulae (V-d) to (V-j); and by a replacement reaction of a corresponding 3,4-dichloro-l,2, 5-thiadiazole derivatives, for the compound of formula(V-b) .
N-
N '/ I R, N
R.
(V-a) (V-b)
(V-d) (V-e) (V-f) (
wherein R1, R2, R3 and L are the same as defined previously. The base which may be used in the above reaction includes an inorganic base such as sodium hydride (NaH), potassium carbonate (K2C03) or sodium methoxide (MeONa), and an organic base such as triethylamine or 1,8- diazabicyclo[5.4.0]undec-7-ene (DBU) .
The above reaction may be conducted in an organic polar solvent such as methanol, acetonitrile, dimethoxyethane, dimethylformamide and the like, at a temperature ranging from 0 to 25 °C, preferably from 0 to 5 °C, for a period ranging from 15 minutes to 2 hours, preferably from 15 to 30 minutes . The present invention also provides pharmaceutical compositions containing the compounds of formula(I) and pharmacologically acceptable salts thereof as active ingredients, in association with pharmaceutically acceptable carriers, excipients or other additives, if necessary. The pharmaceutical compositions of the present invention may be administered orally or by injection. The pharmaceutical composition for oral administration may take various forms such as tablets, granules, solutions and gelatin capsules, which may contain conventional additives such as a diluent, lubricant, absorbent, colorant, favour, sweetener and the like. The composition for injection may be an isotonic solution or a suspension, and may be sterilized and/or contain an adjuvant such as a preservative, stabilizer, wetting agent, emulsifier, a salt for controlling an osmotic pressure and/or a buffer solution, and other pharmaceutically effective materials.
The pharmaceutical composition may be administered for the treatment of fungal infections in a dosage ranging from 0.05 to 10 mg/kg/day, more preferably from 1.0 to 5 mg/kg/day, depending on the routes and frequency of administration, although the dosage may vary in accordance with the kind and severity of the disease. The following Examples are given for the purpose of illustration only and are not intended to limit the scope of the invention.
Example 1 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-t-butyl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
A mixture of 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane, 0.523 g (0.003 mol) of 3-t-butyl-l,2,4- thiadiazol-5-thiol and 0.319 g (0.003 mol) of lithium perchlorate in 6 ml of acetonitrile was stirred at 90 ± 3 °C for 10 hours. The reaction mixture was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography and recrystallized from isopropyl ether/n-hexane to afford the title compound.
M.p. : 138 to 141 °C
1H-NMR(CDC13, δ, ppm) 1.30(d, 3H), 1.43(s, 9H), 4.50(q, 1H), 4.84 and 5.05(dd, 2H), 6.27(s, 1H), 6.74-7.47(m, 3H), 7.71 and 7.88(ss, 2H)
Example 2 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-methylthio-l,2,4-thiadiazol-5-yl)thio-l-( 1H-1,2, 4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- γl) ethyl]oxirane and 0.523 g (0.003 mol) of 3-methylthio- 1,2, 4-thiadiazol-5-thiol to afford the title compound. M.p. : 149 to 154 °C H-NMR(DMSO-d6, δ, ppm) 1.24(d, 3H), 2.65(s, 3H), 4.57(q, 1H), 4.79(s, 2H), 6.62(s, 1H) , 6.98-7.27(m, 3H), 7.67 and 8.21(ss, 2H)
Example 3 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- ( 3-cyclopropyl-l , 2 , 4-thiadiazol-5-yl)thio-1- ( 1H-1 , 2 , 4- triazol-1-yl)-2-butanol
A mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-mercapto-l-( 1H-1, 2, 4-triazol-l-yl ) -2- butanol, 0.48 g (0.003 mol) of 5-chloro-3-cyclopropyl-l, 2,4- thiadiazole and 1.012 g (0.010 mol) of triethylamine in 6 ml of acetonitrile was stirred at 20 ± 2 °C for 30 minutes. The reaction mixture was evaporated under reduced pressure, diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography to afford the title compound. M.p. : 159 to 161 °C 1H-NMR(CDC13, δ, ppm) 1.13-1.32(m, 4H) , 1.26(d, 3H), 2.35(s, 1H), 4.51(q, 1H), 4.88 and 5.00(dd, 2H), 6.18(s, 1H), 6.77- 7.50(m, 3H), 7.77 and 8.88(ss, 2H)
Example 4 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-isopropyl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.488 g (0.003 mol) of 5-chloro-3-isopropyl-l, 2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2, 4- thiadiazole to afford the title compound. M.p. : 147 to 149 °C
1H-NMR(CDC13, δ, ppm) 1.26-1.42(m, 9H), 3.32(m, 1H), 4.53(q, 1H), 4.90 and 5.05(dd, 2H), 6.75-7.50(m, 3H) , 7.77 and 7 . 90 ( ss , 2H )
Example 5 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (,3-methoxy-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.452 g (0.003 mol) of 5-chloro-3-methoxy-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole to afford the title compound. M.p. : 155 to 158 °C
1H-NMR(CDC13, δ, ppm) 1.29(d, 3H), 4.11(s, 3H) , 4.61(q, 1H), 4.90 and 5.02(dd, 2H), 6.70-7.50(m, 3H), 7.77 and 7.83(ss, 2H)
Example 6 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-chloromethyl-l,2,4-thiadiazol-5-yl)thio-l-( 1H-1, 2, 4- triazol-1-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.507 g (0.003 mol) of 5-chloro-3-chloromethyl-l, 2, - thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole to afford the title compound. M.p. : 110 to 113 °C 1H-NMR(CDC13, δ, ppm) 1.36(d, 3H) , 4.78(q, 1H), 4.81(s, 2H), 4.92 and 5.12(dd, 2H), 6.85-7.60(m, 3H), 7.83 and 7.90(ss, 2H)
Example 7 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- ( 3-dimethylamino-l,2,4-thiadiazol-5-yl)thio-1-( 1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.491 g (0.003 mol) of 5-chloro-3-dimethylamino-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole to afford the title compound. M.p. : 120 to 123 °C 1H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 3.22(d, 6H), 4.51(q, 1H), 4.93 and 5.03(dd, 2H), 6.00(s, IH), 6.75-7.55(m, 3H), 7.76 and 7.88(ss, 2H)
Example 8 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- [3-(pyrrolidin-1-yl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-l-yl)-2-butanol oxalate
The same procedures as in Example 3 above were repeated using 0.569 g (0.003 mol) of 5-chloro-3-(pyrrolidin-1-yl)- 1,2,4-thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 91 to 95 °C
1H-NMR(DMSO-d6, δ, ppm) 1.19(d, 3H), 2.90(m, 4H), 3.49(m, 4H), 4.68(q, IH), 4.77 and 4.93(dd, 2H), 6.80-7.30(m, 3H), 7.65 and 8.29(ss, 2H)
Example 9 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-amino-l , 2,4-thiadiazol-5-yl)thio-1-( 1H-1,2,4-triazol-l- yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.407 g (0.003 mol) of 5-chloro-3-amino-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2,4- thiadiazole to afford the title compound. M.p. : 130 to 132 °C
1H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 4.50(q, IH), 4.90-5.20(m, 4H), 5.14(s, IH), 6.76-7.50(m, 3H), 7.81 and 7.97(ss, 2H)
Example 10 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-ethoxy-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.494 g (0.003 mol) of 5-chloro-3-ethoxy-l,2, 4- thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2, 4- thiadiazole to afford the title compound. M.p. : 154 to 158 °C 1H-NMR(CDC13, δ, ppm) 1.27(d, 3H), 1.49(t, 3H), 4.49(q, 2H), 4.60(q, IH), 4.95(dd, 2H), 5.64(s, IH), 6.65-7.48(m, 3H) , 7.79 and 7.83(ss, 2H)
Example 11 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- ( 3-methacryl-l, 2 , 4-thiadiazol-5-yl )thio-1- ( 1H-1 , 2 , 4- triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.482 g (0.003 mol) of 5-chloro-3-methacryl-l, 2, 4- thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2,4- thiadiazole to afford the title compound. M.p. : 116 to 118 °C
1H-NMR(DMSO-d6, δ, ppm) 1.25(d, 3H), 2.18(s, 3H), 4.84(m, 3H), 5.65 and 6.27(d, 2H), 6.58(s, IH), 7.00-7.29(m, 3H), 7.67 and 8.29(ss, 2H)
Example 12 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-methylthiomethyl-l , 2 , 4-thiadiazol-5-yl )thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.542 g (0.003 mol) of 5-chloro-3-methylthiomethyl- 1,2,4-thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 129 to 132 °C
1H-NMR(DMSO-d6, δ, ppm) 1.25(d, 3H), 2.17(s, 3H), 3.92(s, 2H), 4.70(q, IH), 4.82(dd, 2H) , 6.62(s, IH), 7.00-7.25(m, 3H), 7.68 and 8.28(ss, 2H)
Example 13 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-ethyl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.446 g (0.003 mol) of 5-chloro-3-ethyl-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 130 to 132 °C 1H-NMR(CDC13, δ, ppm) 1.34(d, 3H), 1.45(t, 3H), 3.02(q, 2H), 4.60(q, IH), 5.00(dd, 2H), 6.10(s, IH), 6.80-7.50(m, 3H), 7.7.8 and 7.91(ss, 2H)
Example 14 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(1-chloroethyl)-1 , 2 ,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.549 g (0.003 mol) of 5-chloro-3-( 1-chloroethyl)-
1,2,4-thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2,4- thiadiazole to afford the title compound.
M.p. : 140 to 143 °C H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 2.00(s, 3H), 4.70(q, 2H), 4.85 and 5.08(dd, 2H), 5.27(m, 2H), 5.70(s, IH), 6.74-
7.45(m, 3H), 7.77 and 7.83(ss, 2H)
Example 15 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-methoxymethyl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1, 2,4- triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.494 g (0.003 mol) of 5-chloro-3-methoxymethyl-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 73 to 76 °C
1H-NMR(CDC13, δ, ppm) 1.20(d, 3H), 3.50(q, IH) , 3.93(s, 2H), 4.22(s, 2H), 4.75 and 5.03(dd, 2H), 5.15(s, IH), 6.69- 7.45(m, 3H), 7.75 and 7.82(ss, 2H)
Example 16 : Synthesis of (2R*, 3R*)-2-(2 ,4-difluorophenyl)- 3- [ 3-(4-methoxystyryl)-1, 2,4-thiadiazol-5-yl]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.758 g (0.003 mol) of 5-chloro-3-(4-methoxystyryl)- 1,2,4-thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 129 to 131 °C
1H-NMR(CDC13, δ, ppm) 1.34(d, 3H), 3.86(s, 3H), 4.75(m, 3H), 5.01(dd, 2H), 5.85(s, IH) , 6.71-7.54(m, 7H), 7.07 and 7.79(dd, 2H), 7.78 and 7.82(ss, 2H)
Example 17 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3,5-dimethylpyrazol-l-yl)-1,2,4-thiadiazol-5-yl]thio- 1-( 1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.644 g (0.003 mol) of 5-chloro-3-(3,5- dimethylpyrazol-l-yl)-l,2,4-thiadiazole in place of 5- chloro-3-cyclopropyl-l,2,4-thiadiazole to afford the title compound. M.p. : 178 to 181 °C
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 2.35 and 2.67(ss, 6H), 4.70 and 5.01(dd, 2H), 5.70(s, IH), 6.06(s, IH), 6.80- 7.45(m, 3H), 7.79 and 7.91(ss, 2H) Example 18 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-crotyl- ,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.482 g (0.003 mol) of 5-chloro-3-crotyl-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole to afford the title compound. M.p. : 95 to 97 °C
1H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 2.01(dd, 3Hx0.75), 2.18(dd, 3HX0.25), 4.64(q, IH) , 4.97(dd, 2H) , 5.78(brs, lHxO.25), 9.57(brs, lHx0.75), 6.17-6.35(m, lHx0.25), 6.60(d, IH), 6.70-7.55(m, 3H), 7.77 and 7.87(ss, 2H)
Example 19 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-fluorostyryl)-l,2,4-thiadiazol-5-yl]thio-1-(1H- l,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.722 g (0.003 mol) of 5-chloro-3-(4-fluorostyryl)- 1, 2, 4-thiadiazole in place of 5-chloro-3-cyclopropyl-l, 2, 4- thiadiazole to afford the title compound. M.p. : 167 to 169 °C
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H) , 4.76(q, IH), 5.03(dd, 2H), 5.81(s, IH), 6.73-7.65(m, 7H), 6.08-7.80(m, 2H), 7.79 and 7.86(ss, 2H)
Example 20 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-(2,2,3, 3-tetrafluoropropoxy ) styryl)-l,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 1.058 g (0.003 mol) of 5-chloro-3-[4-(2, 2, 3, 3- tetrafluoropropoxy)styryl]-l,2,4-thiadiazole in place of 5- chloro-3-cyclopropyl-l,2,4-thiadiazole to afford the title compound.
M.p. : 109 to 111 °C
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H) , 4.40(t, 2H), 4.74(q, IH), 5.11(dd, 2H), 5.82(s, IH), 5.52, 6.08 and 6.38(t, IH), 6.73- 7.59(m, 7H)," 7.10 and 7.79(dd, 2H), 7.79 and 7.87(ss, 2H)
Example 21 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-fluoromethyl-1,2,4-thiadiazol-5-yl)thio-1-( IH-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 3 above were repeated using 0.458 g (0.003 mol) of 5-chloro-3-fluoromethyl-1,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole to afford the title compound. M.p. : 106 to 108 °C
1H-NMR(CDC13, δ, ppm) 1.31(d, 3H), 4.68(q, IH) , 4.91 and 5.03(dd, 2H), 5.44 and 5.67(dd, 2H), 5.65(ε, IH), 6.78- 7.50(m, 3H), 7.80 and 7.84(ss, 2H)
Example 22 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-phenoxymethyl-l,2,4-thiadiazol-5-yl)thio-1-( 1H-1,2, 4- triazol-l-yl)-2-butanol HCl The same procedures as in Example 3 above were repeated using 0.680 g (0.003 mol) of 5-chloro-3-phenoxymethyl-l,2,4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole and then the resulting product was recrystallized from ethylether by the addition of 5 ml of HCl-saturated ethyl ether to afford the title compound. M.p. : 143 to 146 °C
1H-NMR(DMSO-d6, δ, ppm) 1.25(d, 3H) , 4.07(m, 2H), 4.87(s, 2H), 5.35(s, 2H), 6.60-7.40(m, 3H), 8.04 and 8.85(ss, 2H)
Example 23 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2-fluorophenyl )-1 , 2 , 4-thiadiazol-5-yl ]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.637 g (0.003 mol) of 3-(2-fluorophenyl)-l,2, - thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol and then the resulting product was recrystallized from diethyl ether to afford the title compound. M.p. : 133 to 136 °C H-NMR(DMSO-d6, δ, ppm) 1.00(d, 3H) , 4.57(m, 3H), 6.34(s, IH), 6.68-7.30(m, 7H), 7.37 and 7.99(ss, 2H)
Example 24 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2, 6-difluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.691 g (0.003 mol) of 3-(2,6-difluorophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiole to afford the title compound. M.p. : 175 to 179 °C
1H-NMR(DMSO-d6, δ, ppm) 1.27(d, 3H), 4.85(m, 3H), 6.63(s, IH), 6.90-7.70(m, 6H), 7.67 and 8.27(ss, 2H)
Example 25 : Synthesis of ( 2R , 3R ) -2- ( 2 , 4-dif luorophenyl ) - 3- [ 3- ( 4-f luorophenyl ) - 1 , 2 , 4-thiadiazol-5 -yl ] thio- 1 - ( 1H- 1 , 2 , 4-triazol-l-yl ) -2-butanol The same procedures as in Example 1 above were repeated using 0.637 g (0.003 mol) of 3-(4-£luorophenyl)-1, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 133 to 138 °C H-NMR(DMSO-d6, δ, ppm) 1.30(d, 3H), 4.90(m, 3H), 6.65(s, IH), 7.02-8.40(m, 7H), 7.70 and 8.25(ss, 2H)
Example 26 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2-pyridyl)-1,2, 4-thiadiazol-5-yl]thio-1-( 1H-1, 2,4- triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.586 g (0.003 mol) of 3-(2-pyridyl)-1,2,4-thiadiazol-
5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound.
M.p. : 174 to 176.5 °C
1H-NMR(CDC13, δ, ppm) 1.37(d, 3H), 4.75(q, IH), 4.95 and 5.09(dd,2H), 5.90(s, IH), 7.40-8.84(m, 7H), 7.77 and
7.91(ss, 2H)
Example 27 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(2-chlorophenyl)-l,2,4-thiadiazol-5-yl]thio-l-( 1H- l,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.686 g (0.003 mol) of 3-(2-chlorophenyl)-l, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 125 to 127.5 °C
1H-NMR(DMSO-d6, δ, ppm) 1.20(d, 3H), 4.88(m, 3H), 6.65(8, IH), 7.00-7.90(m, 6H), 7.70 and 8.30(ss, 2H)
Example 28 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-phenyl-l ,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol The same procedures as in Example 1 above were repeated using 0.583 g (0.003 mol) of 3-phenyl-l,2,4-thiadiazol-5- thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 135 to 138 °C
1H-NMR(DMSO-d6, δ, ppm) 1.31(d, 3H), 4.82(m, 3H), 6.63(s, IH), 7.02-8.21(m, 8H) , 7.68 and 8.29(ss, 2H)
Example 29 : Synthesis of (2R*, 3R*)-2-(2, -difluorophenyl)- 3- [ 3- ( 3-pyridyl)-1, 2,4-thiadiazol-5-yl ]thio-1-( 1H-1, 2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.586 g (0.003 mol) of 3-(3-pyridyl)-l,2,4-thiadiazol- 5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 146 to 149 °C H-NMR(CDC13, δ, ppm) 1.36(d, 3H), 4.90(m, IH) , 4.95 and 5.11(dd, 2H), 5.66(s, IH), 6.78-9.56(m, 6H), 7.80 and 7.81(ss, 2H)
Example 30 : Synthesis of ( 2R* , 3R* ) -2- ( 2 , 4-dif luorophenyl ) - 3 - [ 3 - ( 4-pyridyl ) -1 , 2 , -thiadiazol-5-yl ] thio- 1- ( 1H- 1 , 2 , 4- triazol-1-yl ) -2-butanol
The same procedures as in Example 1 above were repeated using 0.586 g (0.003 mol) of 3-(4-pyridyl)-l,2,4-thiadiazol- 5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 178 to 180 °C
1H-NMR(CDC13, δ, ppm) 1.37(d, 3H) , 4.90(m, IH), 4.95 and 5.09(dd, 2H), 5.66(s, IH), 6.80-7.46(m, 3H), 7.81 and 7.81(ss, 2H), 8.13-8.80(m, 4H)
Example 31 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 4- ( 1-(N-hydroxyiminoethyl)phenyl)-1, 2 , 4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol The same procedures as in Example 1 above were repeated using 0.754 g (0.003 mol) of 4-(1-(N-hydroxyiminoethyl) phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t-butyl- l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 177 to 180 °C
1H-NMR(CDC13, δ, ppm) 1.37(d, 3H) , 4.88(m, IH), 4.96 and 5.12(dd, 2H), 5.84(s, IH), 6.80-7.87(m, 7H), 8.30 and 8.37(ss, 2H), 9.33(s, IH)
Example 32 : Synthesis of (2R*, 3R*)-2-(4-chlorophenyl)-3-[3- (3,5-difluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.499 g (0.002 mol) of (2R*, 3S*)-2-(4-chlorophenyl)-3- methyl-2-[ (1H-1,2,4-triazol-l-yl)methyl]oxirane and 0.691 g (0.003 mol) of 3-(3,5-difluorophenyl)-1,2,4-thiadiazol-5- thiol in place of (2R*, 3S*)-2-(2,4-difluorophenyl)-3-methyl- 2-[ (1H-1,2,4-triazol-l-yl)methyl]oxirane and 3-t-butyl- 1,2,4-thiadiazol-5-thiol, respectively, to afford the title compound.
M.p. : 104 to 106 °C
1H-NMR(DMSO-d6, δ, ppm) 1.34(d, 3H), 4.50(m, IH), 4.90(dd, 2H), 6.44(s, IH), 7.44-7.85(m, 6H), 7.87 and 8.24(ss, 2H)
Example 33 : Synthesis of (2R*, 3R*)-2-(2,4-dichlorophenyl)- 3-[3-(4-pyridyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.499 g (0.002 mol) of (2R*, 3S*)-2-(2,4- dichlorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.586 g (0.003 mol) of 3-(4-pyridyl)- l,2,4-thiadiazol-5-thiol in place of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 3-t-butyl-l,2,4-thiadiazol-5-thiol, respectively, to afford the title compound. M.p. : 142 to 144 °C 1H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 4.90 and 5.63(dd, 2H), 5.45(q, IH), 5.70(s, IH), 7.15-7.60(m, 3H), 7.81(s, 2H), 8.15-8.18(m, 4H)
Example 34 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-chlorophenyl)-l,2,4-thiadiazol-5-yl]thio-l-( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.686 g (0.003 mol) of 3-(4-chlorophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound.
M.p. : 156 to 159 °C
1H-NMR(DMSO-d6, δ, ppm) 1.30(d, 3H), 4.85(m, 3H), 6.64(s, IH), 6.95-8.23(m, 7H), 7.68 and 8.27(ss, 2H)
Example 35 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-( 3-fluorophenyl ) -1, 2 , 4-thiadiazol-5-yl ]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.637 g (0.003 mol) of 3-(3-fluorophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 123 to 125 °C H-NMR(CDC13, δ, ppm) 1.36(d, 3H) , 4.88(m, IH), 5.10(dd, IH), 5.68(s, IH), 6.70-8.20(m, 7H), 7.79 and 7.82(ss, 2H)
Example 36 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3,4-difluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.691 g (0.003 mol) of 3-(3,4-difluorophenyl)-l, 2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 137 to 139.5 °C 1H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 4.88(q, IH), 5.01(dd, 2H), 5 . 65 ( ε , IH ) , 6 . 70- 8 . 20 (m, 6H ) , 7 . 80 ( s , 2H )
Example 37 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2, 6-dichlorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- l,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.790 g (0.003 mol) of 3-(2, 6-dichlophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 138 to 140 °C H-NMR(CDC13, δ, ppm) 1.29(d, 3H), 4.85(m, 3H), 5.71(s, IH), 6.95-7.80(m, 6H), 7.70 and 8.32(ss, 2H)
Example 38 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3-trifluoromethylphenyl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.787 g (0.003 mol) of 3-(3-trifluoromethylphenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l, 2,4- thiadiazol-5-thiol to afford the title compound.
M.p. : 144 to 146 °C
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 4.90(q, IH), 5.08(dd, 2H), 5.59(s, IH), 6.70-8.65(m, 7H), 7.77 and 7.82(sε, 2H)
Example 39 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3-chlorophenyl)-l, 2 , 4-thiadiazol-5-yl ]thio-l- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.686 g (0.003 mol) of 3-(3-chlorophenyl)-l,2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4-thiadiazol-5- thiol to afford the title compound. M.p. : 118 to 120 °C
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H) , 4.87(q, IH), 5.02(dd, 2H), 5.64(s, IH), 6.72-8.32(m, 7H), 7.79 and 7.82(ss, 2H) Example 40 : Synthesis of (2R*, 3R*)-2-(2, 4-difluorophenyl)- 3-[3-(4-( lH-imidazol-1-yl)phenyl )-l, 2, 4-thiadiazol-5- yl]thio-1-( 1H-1, 2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.781 g (0.003 mol) of 3-(4-( lH-imidazol-1-yl)phenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2,4- thiadiazol-5-thiol to afford the title compound. M.p. : 227 to 230 °C 1H-NMR(CDC13, δ, ppm) 1.38(d, 3H), 4.90(m, IH), 4.97 and 5.09(dd, 2H), 5.75(s, IH), 6.80-7.83(m, 7H) , 7.27 and 7.99(ss, 2H), 8.40 and 8.45(ss, 2H)
Example 41 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(2-pyrazinyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.589 g (0.003 mol) of 3-(2-pyrazinyl)-l, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 157 to 160 °C
1H-NMR(CDC13, δ, ppm) 1.36(d, 3H), 4.86(m, 3H) , 4.95 and 5.10(dd, 2H), 5.72(s, IH) , 6.70-7.50(m, 3H), 7.80 and 8.83(ss, 2H), 8.73 and 9.60(m, 3H)
Example 42 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(2-chloro-6-fluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2, -triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.740 g (0.003 mol) of 3-(2-chloro-6-fluorophenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4- thiadiazol-5-thiol to afford the title compound. M.p. : 117 to 119 °C
1H-NMR(CDC13, δ, ppm) 1.32(d, 3H), 4.70(q, IH), 5.16(dd, 2H), 5.73(s, IH), 6.67-7.55(m, 6H), 7176 and 7.84(ss, 2H) Example 43 : Synthesis of (2R*, 3R*)-2-(2, 4-difluorophenyl)- 3-[3-(4-bromophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.820 g (0.003 mol) of 3-(4-bromophenyl)-1, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 163 to 165 °C 1H-NMR(DMSO-d6, δ, ppm) 1.29(d, 3H), 4.85(m, 3H), 6.64(s, IH), 7.00-8.10(m, 7H), 7.68 and 8.28(ss, 2H)
Example 44 : Synthesis of (2R*, 3R*)-2-(2, -difluorophenyl)- 3-[ 3-(4-( 1H-1,2, -triazol-l-yl)phenyl)-1,2,4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.784 g (0.003 mol) of 3-(4-(1H-1,2,4-triazol-l- yl)phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t-butyl- l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 193 to 196 °C
1H-NMR(CDC13, δ, ppm) 1.38(d, 3H), 4.90(m, IH), 4.96 and 5.10(dd, 2H), 5.70(s, IH), 6.80-7.90(m, 7H), 8.17 and 8.43(ss, 2H), 8.47 and 8.69(ss, 2H)
Example 45 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-azidophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.706 g (0.003 mol) of 3-(4-azidophenyl)-1, 2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- 'thiol to afford the title compound. M.p. : 123 to 125 °C 1H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 4.86(q, IH), 4.94 and 5.08(dd, 2H), 5.77(s, IH) , 6.80-8.33(m, 7H), 7.78 and 7.83(ss, 2H) Example 46 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-( 3, 5-bistrifluoromethylphenyl) -1,2, 4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.991 g (0.003 mol) of 3-(3,5- bistri luoromethylphenyl)-1,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 123 to 125 °C H-NMR(DMSO-d6, δ, ppm) 1.29(d, 3H), 4.90(m, 3H), 6.63(s, IH), 7.00-8.40(m, 6H), 8.60 and 8.70(ss, 2H)
Example 47 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-styryl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.661 g (0.003 mol) of 3-styryl-l,2,4-thiadiazol-5- thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 151 to 153 °C
1H-NMR(CDC13, δ, ppm) 1.36(d, 3H), 4.68(q, IH), 4.96 and 5.05(dd, 2H), 5.50(s, IH), 6.78-7.63(m, 8H), 7.08 and 7.68(dd,2H), 7.82(ss, 2H)
Example 48 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-morpholin-l-yl)phenyl-l,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.838 g (0.003 mol) of 3-(4-morpholin-l-yl)phenyl- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l, 2,4- thiadiazol-5-thiol to afford the title compound. M.p. : 169 to 171 °C H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 3.31 and 3.90(m, 8H), 4.75(q, IH), 4.93 and 5.09(dd, 2H), 6.05(s, IH), 6.79- 8.02(m, 7H), 7.76 and 7.87(ss, 2H) Example 49 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 3- ( 3-trifluoromethyl-4-acetylamino )phenyl-l,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.958 g (0.003 mol) of 3-(3-trifluoromethyl-4- acetylamino)phenyl-1,2,4-thiadiazol-5-thiol in place of 3-t- butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 123 to 125 °C 1H-NMR(DMSO-d6, δ, ppm) 1.29(d, 3H), 2.11(s, 3H), 4.88(m, 3H), 6.63(s, IH), 7.00-8.40(m, 6H), 7.67 and 8.28(ss, 2H), 9.72(s, IH)
Example 50 : Synthesis of (2R*, 3R*)-2-(2, 4-difluorophenyl)- 3-[3-(4-(l,3, 4-oxadiazol-2-yl)phenyl)-1, 2, 4-thiadiazol-5- yl]thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.787 g (0.003 mol) of 3-(4-( 1, 3, 4-oxadiazol-2- yl)phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t-butyl- l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 122 to 125 °C
1H-NMR(DMSO-d6, δ, ppm) 1.35(d, 3H), 4.90(m, 3H), 6.68(s, IH), 7.00-8.42(m, 7H), 7.72 and 8.32(ss, 2H), 9.46(s, IH)
Example 51 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 3- (4- ( 1 , 3-dioxolan-2-yl)phenyl)-l, 2, 4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.799 g (0.003 mol) of 3-(4-(1, 3-dioxolan-2- yl)phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t-butyl- l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 138 to 140 °C 1H-NMR(DMSO-d6, δ, ppm) 1.31(d, 3H), 4.04-4.14(m, 4H), 4.83(m, IH), 4.89 and 5.06(dd, 2H), 5.74(s, IH), 5.86(s, IH), 6.70-8.30(m, 7H), 7.74 and 7.78(sε, 2H) Example 52 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-cyanophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.658 g (0.003 mol) of 3-(4-cyanophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 195 to 197 °C 1H-NMR(CDC13, δ, ppm) 1.37(d, 3H), 4.88(q, IH), 4.96 and 5.07(dd, 2H), 5.60(s, IH), 6.75-8.44(m, 7H), 7.81 and 7.84(ss, 2H)
Example 53 : Syntheεiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(thiophen-2-yl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.601 g (0.003 mol) of 3-(thiophen-2-yl)-1, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 122 to 125 °C
1H-NMR(DMSO-d6, δ, ppm) 1.28(d, 3H), 4.83(m, 3H), 6.60(s, IH), 7.00-7.82(m, 6H), 7.67 and 8.29(sε, 2H)
Example 54 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-nitrophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-l-yl)-2-butanol oxalate
The same procedureε aε in Example 1 above were repeated uεing 0.718 g (0.003 mol) of 3-(4-nitrophenyl)-l,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4-thiadiazol-5- thiol, and to the compound thuε obtained was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound. M.p. : 169 to 172 °C
1H-NMR(DMSO-d6, δ, ppm) 1.29(d, 3H), 4.87(m, 3H), 6.58(s, IH), 6.67-7.91(m, 7H), 7.67 and 8.30(sε, 2H) Example 55 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(pyrimidin-5-yl)-l, 2 , 4-thiadiazol-5-yl ]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures aε in Example 1 above were repeated uεing 0.589 g (0.003 mol) of 3-(pyrimidin-5-yl)-1, 2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4-thiadiazol-5- thiol to afford the title compound. M.p. : 140 to 143 °C 1H-NMR(DMSO-d6, δ, ppm) 1.30(d, 3H), 4.90(m, 3H), 6.61(s, IH), 7.00-7.30(rn, 3H), 7.88 and 8.28(sε, 2H), 9.35 and 9.41(d, 3H)
Example 56 : Syntheεiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-biphenyl)-l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4- triazol-1-yl)-2-butanol
The same procedures aε in Example 1 above were repeated uεing 0.811 g (0.003 mol) of 3-(4-biphenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 127 to 129 °C
1H-NMR(CDC13, δ, ppm) 1.40(d, 3H), 4.84(q, IH) , 5.01(dd, 2H), 5.82(s, IH), 6.70-7.85(m, 12H) , 8.38 and 8.41(εs, 2H)
Example 57 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-(2,2,3, 3-tetrafluoropropoxy) phenyl ) -1 , 2 , 4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.973 g (0.003 mol) of 3-(4-(2,2, 3, 3-tetrafluoro- propoxy)phenyl)-l,2,4-thiadiazol-5-thiol in place of 3-t- butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 140 to 142 °C 1H-NMR(CDC13, δ, ppm) 1.39(d, 3H), 4.48(q, IH), 5.09(dd, 2H), 5.82(s, IH), 5.83, 6.15 and 6.40(t, IH) , 6.75-7.83(m, 7H), 8.27 and 8.32(ss, 2H) Example 58 : Synthesiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-(4-pyridon-l-yl)phenyl)-1,2,4-thiadiazol-5-yl]thio- 1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.862 g (0.003 mol) of 3-(4-(4-pyridon-l-yl)phenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4- thiadiazol-5-thiol to afford the title compound. M.p. : 235 to 238 °C 1H-NMR(DMSO-d6, δ, ppm) 1.32(d, 3H), 4.90(q, 3H), 6.33 and 8.11(dd, 4H), 6.66(s, IH) , 6.88-8.37(m, 7H), 7.69 and 8.30(ss, 2H)
Example 59 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-methylpyrimidin-2-yl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures aε in Example 1 above were repeated uεing 0.631 g (0.003 mol) of 3-(4-methylpyrimidin-2-yl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2,4- thiadiazol-5-thiol to afford the title compound. M.p. : 235 to 238 °C
1H-NMR(DMSO-d6, δ, ppm) 1.38(d, 3H), 2.65(ε, 3H) , 4.80(m, IH), 4.93(s, 2H), 6.77(s, IH), 7.07-7.38(m, 3H), 7.61 and 8.91(dd, 2H), 7.69 and 8.30(ss, 2H)
Example 60 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(pyridin-N-oxo-4-yl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures aε in Example 1 above were repeated using 0.634 g (0.003 mol) of 3-(pyridin-N-oxo-4-yl)-l,2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 201 to 204 °C
1H-NMR(DMSO-d6, δ, ppm) 1.33(d, 3H), 4.70-5.00(m, 3H), 6.67(s, 4H), 6.90-7.10(m, 3H), 7.72 and 8.31(ss, 2H), 8.10- 8.40(m, 4H) Example 61 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(4-methylthiophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.721 g (0.003 mol) of 3-(4-methylthiophenyl)-l,2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4-thiadiazol-5- thiol to afford the title compound. M.p. : 140 to 143 °C 1H-NMR(DMSO-d6, δ, ppm) 1.30(d, 3H) , 2.67(s, 3H), 4.80(m, 3H), 6.61(ε, IH), 7.00-8.15(m, 7H), 7.00 and 8.30(εs, 2H)
Example 62 : Synthesiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-methanesulfonylphenyl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.817 g (0.003 mol) of 3-(4-methanesulfonylphenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l, 2, 4- thiadiazol-5-thiol to afford the title compound. M.p. : 172 to 174 °C H-NMR(DMSO-d6, δ, ppm) 1.33(d, 3H), 3.31(s, 3H), 4.90(m, 3H), 6.64(s, IH), 7.00-8.45(m, 7H), 7.70 and 8.29(sε, 2H)
Example 63 : Syntheεis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3-nitrophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated uεing 0.718 g (0.003 mol) of 3-(3-nitrophenyl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound.
M.p. : 115 to 118 °C
1H-NMR(DMSO-d6, δ, ppm) 1.32(d, 3H) , 4.88(m, 3H), 6.66(ε, IH), 7.05(m, IH), 7.32(m, 2H) , 7.69(ε, IH), 7.90(t, IH),
8.29(ε, IH), 8.40 and 8.55(d, 2H)
Example 64 : Synthesiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[ 3-(2,5-difluorophenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.691 g (0.003 mol) of 3-(2,5-difluorophenyl)-l,2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 151 to 153 °C
1H-NMR(DMSO-d6, δ, ppm) 1.31(d, 3H), 4.89(m, 3H), 6.64(s, IH), 7.05-7.90(m, 3H) , 7.70 and 8.31(sε, 2H)
Example 65 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(4-dimethylaminophenyl)-1,2,4-thiadiazol-5-yl]thio-1- (1H-1,2,4-triazol-l-yl)-2-butanol
The same procedureε as in Example 1 above were repeated using 0.712 g (0.003 mol) of 3-(4-dimethylaminophenyl)- l,2,4-thiadiazol-5-thiol in place of 3-t-butyl-l,2,4- thiadiazol-5-thiol to afford the title compound. M.p. : 160 to 163 °C
1H-N R(DMSO-d6, δ, ppm) 1.31(d, 3H), 3.03(s, 6H), 4.89(m, 3H), 6.61(s, IH), 6.84-8.05(m, 3H), 7.69 and 8.32(sε, 2H)
Example 66 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(lH-l,2,4-triazol-l-yl)methyl-l,2,4-thiadiazol-5- yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol
The same procedureε as in Example 3 above were repeated using 0.640 g (0.003 mol) of 5-chloro-3-bromomethyl-l,2, 4- thiadiazole in place of 5-chloro-3-cyclopropyl-l,2, 4- thiadiazole and adding 0.364 g (0.004 mol) of triazole- Na εalt to the εtirred reaction mixture to afford the title compound.
M.p. : 136 to 140 °C H-NMR(DMSO-d6, δ, ppm) 1.23(d, 3H) , 3.60(q, IH), 4.16(q,
2H), 4.78 and 5.06(dd, 2H), 5.10(8, IH), 6.71-7.50(m, 3H),
7.41, 7.78, 8.19 and 9.14(q, 4H) Example 67 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 3- (4-methoxystyryl)-1, 2,4-thiadiazol-5-yl]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedureε aε in Example 3 above were repeated uεing 0.758 g (0.003 mol) of 5-chloro-3-(4-methoxystyryl)- 1,2,4-thiadiazole in place of 5-chloro-3-cyclopropyl-l,2,4- thiadiazole to afford the title compound. M.p. : 129 to 131 °C 1H-NMR(DMSO-d6, δ, ppm) 1.06(d, 3H) , 3.70(q, IH), 4.63 and 4.83(dd, 2H), 6.03(8, IH), 6.38-8.37(dd, 2H), 6.90-7.24(m, 3H), 7.62 and 8.23(sε, 2H)
Example 68 : Syntheεis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(3-pyrrol-l-yl)phenyl-l,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.778 g (0.003 mol) of 3-(3-pyrrol-l-yl)phenyl-l,2, 4- thiadiazol-5-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol to afford the title compound. M.p. : 84 to 86 °C
1H-NMR(DMSO-d6, δ, ppm) 1.38(d, 3H), 5.02(m, 3H), 6.44(s, 2H), 6.71(8, IH), 7.10-8.41(11., 11H), 7.75 and 8.38(ss, 2H)
Example 69 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(pyridazin-3-yl)-l,2,4-thiadiazol-5-yl]thio-l-( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures aε in Example 1 above were repeated uεing 0.589 g (0.003 mol) of 3-(pyridazin-3-yl)-1,2,4- thiadiazol-5-thiol in place of 3-t-butyl-l,2, 4-thiadiazol-5- thiol to afford the title compound. M.p. : 168 to 170 °C 1H-NMR(CDC13, δ, ppm) 1.38(d, 3H), 4.80(q, IH), 4.90 and 5.12(dd, 2H), 5.80(ε, IH), 6.75-7.55(m, 3H), 7.65-9.35(m, 3H), 7.78 and 7.90(ss, 2H) Example 70 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(l-chloro-2-methoxyethyl)-1,2,4-thiadiazol-5-yl]thio-1- (lH-l,2,4-triazol-l-yl)-2-butanol- HC1
A mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol, 0.636 g (0.003 mol) of 5-chloro-3-(l-chloro-2- methoxyethyl)-l,2,4-thiadiazole and 0.108 g (0.002 mol) of sodium methoxide in 5 ml of methanol was stirred at 0 °C for about 15 minutes. The reaction mixture was proceεsed aε in Example 3 above and recyεtallized from ethyl ether by the addition of HCl-saturated ethyl ether to afford the title compound. M.p. : 178 to 180 °C 1H-NMR(DMSO-d6, δ, ppm) 1.27(d, 3H) , 3.31(ε, 3H), 4.00(m, 2H), 4.74(q, IH), 4.89(ε, 2H), 5.44(m, IH), 6.90-7.40(m, 3H), 8.00 and 8.82(ss, 2H)
Example 71 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(3-methoxymethyl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
A mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol, 0.640 g (0.003 mol) of 5-chloro-3-bromomethyl- 1,2,4-thiadiazole and 0.324 g (0.006 mol) of sodium methoxide in 5 ml of methanol was stirred at 0 °C for about 15 minutes. The reaction mixture was procesεed as in Example 3 above to afford the title compound. M.p. : 73 to 76 °C H-NMR(CDC13, δ, ppm) 1.20(d, 3H), 3.55(q, IH), 3.93(q, 2H), 4.22(8, 3H), 4.72 and 5.03(dd, 2H), 5.15(ε, IH), 6.69- 7.45(m, 3H), 7.75 and 7.82(ss, 2H)
Example 72 : Synthesis of (2R, 3R)-2-(2,4-difluorophenyl)-3- (3-styryl-l,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol The same procedures as in Example 3 above were repeated using 0.571 g (0.002 mol) of (2R, 3R)-2-(2,4- difluorophenyl)-3-mercapto-l- (lH-l,2,4-triazol-l-yl)-2- butanol and 0.668 g (0.003 mol) of 5-chloro-3-styryl-l, 2,4- thiadiazole in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- mercapto-l-(lH-l,2,4-triazol-l-yl)-2-butanol and 5-chloro-3- cyclopropyl-l,2,4-thiadiazole, reεpectively, to afford the title compound. Thereto was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford an oxalate of the title compound. To the title compound was added 0.192 g (0.002 mol) of methanesulfonic acid in the presence of ethylether to afford a methanesulfonate of the title compound. M.p. : 125 °C (oxalate) M.p. : 88 to 91 °C (methanesulfonate)
1H-NMR(CDC13, δ, ppm) 1.35(d, 3H), 4.77(q, IH), 5.05(dd, 2H), 6.73-7.68(dd, 3H), 7.20 and 7.85(dd, 2H), 7.85 and 8.21(εε, 2H)
Example 73 : 'Synthesis of (2R, 3R)-2-(2,4-difluorophenyl)-3- (3-methoxy-l,2, -thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
The same procedures as in Example 5 above were repeated using 0.571 g (0.002 mol) of (2R, 3R)-2-(2,4- difluorophenyl)-3-mercapto-l- ( 1H-1, 2, 4-triazol-l-yl) -2- butanol in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3- mercapto-2-( 1H-1,2,4-triazol-l-yl)-2-butanol to afford the title compound. Thereto was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford an oxalate of the title compound. M.p. : 77 to 79 °C M.p. : 107 to 110 °C (oxalate) lH-NMR(DMSO-d6, δ, ppm) 1.21(d, 3H) , 4.78(s, 3H) , 4.62(q, IH), 4.78(s, 2H), 6.66(s, IH) , 6.82-7.38(m, 3H) , 7.66 and 8.26(εs, 2H)
Example 74 : Synthesis of (2R*, 3R*)-2-(4-chlorophenyl)-3-(3- methoxy-1,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
The same procedureε as in Example 5 above were repeated using 0.568 g (0.002 mol) of (2R*, 3R*)-2-(4-chlorophenyl)-3- mercapto-l-(lH-l,2,4-triazol-l-yl)-2-butanol in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3-mercapto-2-(1H-1,2,4- triazol-l-yl)-2-butanol to afford the title compound. M.p. : 93 to 95 °C lH-NMR(DMSO-d6, δ, ppm) 1.25(d, 3H), 3.98(s, 3H), 4.30(q, IH), 4.82(d, 2H), 6.35(8, IH), 7.33(s, 4H), 7.82 and 8.17(ss, 2H)
Example 75 : Synthesis of (2R*, 3R*)-2-(4-fluorophenyl)-3-(3- methoxy-1,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
The same procedures as in Example 5 above were repeated using 0.535 g (0.002 mol) of (2R*, 3R*) -2-(4-fluorophenyl)-3- mercapto-l-(lH-l,2,4-triazol-l-yl)-2-butanol in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3-mercapto-2-(1H-1,2,4- triazol-l-yl)-2-butanol to afford the title compound. M.p. : 111 to 113 °C lH-NMR(DMSO-d6, δ, ppm) 1.29(d, 3H), 4.00(s, 3H) , 4.43(q, IH), 4.83(d, 2H) , 6.36(ε, IH), 7.17-7.43(m, 4H), 7.86 and 8.19(ss, 2H)
Example 76 : Synthesis of (2R*, 3R*)-2-(4-fluorophenyl)-3-(3- styryl-1,2,4-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)- 2-butanol
The same procedureε aε in Example 3 above were repeated uεing 0.535 g (0.002 mol) of (2R*, 3R*)-2-(4-fluorophenyl)-3- mercapto-l-(lH-l,2,4-triazol-l-yl)-2-butanol and 0.668 g (0.003 mol) of 5-chloro-3-styryl-l,2,4-thiadiazole in place of (2R*, 3R*)-2-(2,4-difluorophenyl)-3-mercapto-2-(1H-1,2,4- triazol-l-yl)-2-butanol and 5-chloro-3-cyclopropyl-l,2,4- thiadiazole, reεpectively, to afford the title compound. M.p. : 126 to 129 °C lH-NMR(DMSO-d6, δ, ppm) 1.35(d, 3H), 4.40(m, IH), 4.90(dd,
2H), 6.30(s, IH), 7.20-7.80(m, 11H), 7.89 and 8.24(sε, 2H)
Example 77 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(2, 6-difluorophenyl)-thiazol-2-yl]thio-1-(1H-1 ,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.688 g (0.003 mol) of 4-(2,6-difluorophenyl)-thiazol-
2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound.
M.p. : 131 to 133 °C
1H-NMR(CDC13, δ, ppm) 1.30(d, 3H), 4.25(q, IH), 5.02(dd, 2H), 6.62-7.56(m, 7H), 7.66 and 8.12(ss, 2H)
Example 78 : Syntheεiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(2,4-dichlorophenyl)-thiazol-2-yl]thio-1-(1H-1 ,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.787 g (0.003 mol) of 4-(2,4-dichlorophenyl)-thiazol- 2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 138 to 140 °C H-NMR(DMSO-d6, δ, ppm) 1.24(d, 3H), 4.78(q, IH), 4.89(s, 2H), 6.49(s, IH), 6.80-7.92(m, 6H), 8.10 and 8.30(ss, 2H)
Example 79 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(4-chlorophenyl)-thiazol-2-yl]thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.683 g (0.003 mol) of 4-(4-chlorophenyl)-thiazol-2- thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 115 to 117 °C H-NMR(CDC13, δ, ppm) 1.30(d, 3H), 4.44(q, IH), 5.01(dd, 2H) , 6 . 59 ( s , IH ) , 6 . 65-7 . 85 (m, 8H ) , 7 . 95 ( s , IH )
Example 80 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(4-ethylthiazol-2-yl)thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol- oxalate
The same procedures as in Example 1 above were repeated using 0.436 g (0.003 mol) of 4-ethylthiazol-2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol and to the compound thus obtained was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound.
M.p. : 108 to 110 °C
1H-NMR(CDC13, δ, ppm) 1.24(d, 3H), 1.34(t, 3H), 2.85(q, 2H), 4.03(q, IH), 5.03(dd, 2H) , 6.70-7.60(m, 3H), 7.88 and
8.63(ss, 2H)
Example 81 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(1-hydroxy-l-methylethyl)-thiazol-2-yl]thio-1-( 1H- l,2,4-triazol-l-yl)-2-butanol- oxalate
The same procedureε aε in Example 1 above were repeated uεing 0.526 g (0.003 mol) of 4-(1-hydroxy-l-methylethyl)- thiazol-2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5- thiol and to the compound thus obtained was added 0.18 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound. M.p. : 106 to 108 °C 1H-NMR(DMSO-d6, δ, ppm) 1.17(d, 3H), 1.47(t, 3H) , 4.67(q, IH), 4.83(dd, 2H) , 6.50(s, IH) , 6.87-7.31(m, 3H) , 7.32(s, IH), 7.63 and 8.31(ss, 2H)
Example 82 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(4-εtyrylthiazol-2-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol
The same procedureε aε in Example 1 above were repeated using 0.658 g (0.003 mol) of 4-styrylthiazol-2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 98 to 100 °C
1H-NMR(CDC13, δ, ppm) 1.31(d, 3H), 4.40(q, IH), 5.07(dd, 2H), 6.70-7.60(m, 11H) , 7.72 and 8.05(ss, 2H)
Example 83 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(4-methoxystyryl)-thiazol-2-yl]thio-l-( IH-1,2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.748 g (0.003 mol) of 4-(4-methoxystyryl)-thiazol-2- thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 138 to 140 °C
1H-NMR(CDC13, δ, ppm) 1.31(d, 3H) , 3.85(ε, 3H), 4.38(q, IH), 5.02(dd, 2H), 6.70-7.60(m, 10H) , 7.71 and 8.05(εε, 2H)
Example 84 : Syntheεiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4- (2, 3-dichlorostyryl)-thiazol-2-yl]thio-1-(1H-1, 2,4- triazol-1-yl)-2-butanol
The same procedures as in Example 1 above were repeated using 0.865 g (0.003 mol) of 4-(2, 3-dichlorostyryl)-thiazol- 2-thiol in place of 3-t-butyl-l,2,4-thiadiazol-5-thiol to afford the title compound. M.p. : 135 to 137 °C
1H-NMR(CDC13, δ, ppm) 1.33(d, 3H), 4.05(q, IH), 5.07(dd, 2H), 6.60(s, IH), 6.65-7.70(m, 7H) , 7.91 and 8.01(ss, 2H)
Example 85 : Synthesiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(1,2, 3-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol
A mixture of 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane, 0.420 g (0.003 mol) of 1,2, 3-thiadiazol- 5-thiol-Na salt and 0.319 g (0.003 mol) of lithium perchlorate in 6 ml of acetonitrile was stirred at 100 °C for 12 hours. The reaction mixture was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which waε purified by εilica gel column chromatography to afford the title compound. M.p. : 129 to 131.5 °C H-NMR(DMSO-d6, δ, ppm) 1.26(d, 3H), 4.20(q, IH), 4.94(8, 2H), 6.73(s, IH), 7.08-7.44(m, 3H), 7.82 and 8.35(sε, 2H), 9.05(8, IH)
Example 86 : Syntheεiε of (2R*, 3R*)-2-(4-chlorophenyl)-3- (1,2, 3-thiadiazol-5-yl)thio-1- (1H-1,2,4-triazol-l-yl )-2- butanol
The same procedures as in Example 85 above were repeated using 0.499 g (0.002 mol) of (2R*, 3S*)-2-(4- chlorophenyl)-3-methyl-2-[ ( lH-l, 2, 4-triazol-l- yl)methyl]oxirane and 0.420 g (0.003 mol) of 1,2,3- thiadiazol-5-thiol- Na salt to afford the title compound. M.p. : 151 to 153 °C H-NMR(DMSO-d6, δ, ppm) 1.27(d, 3H), 4.20(q, IH), 4.96(s, 2H), 6.46(s, IH), 7.48(m, 4H), 7.96 and 8.28(sε, 2H), 9.04(s, IH)
Example 87 : Synthesis of (2R*, 3R*)-2-(2,4-dichlorophenyl)- 3-(1,2, 3-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol
The same procedures as in Example 85 above were repeated using 0.568 g (0.002 mol) of (2R*, 3S*)-2-(2,4- dichlorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.420 g (0.003 mol) of 1,2,3- thiadiazol-5-thiol- Na salt to afford the title compound. M.p. : 158 to 160 °C 1H-NMR(DMSO-d6, δ, ppm) 1.18(d, 3H), 4.65(q, IH) , 5.10(dd, 2H), 6.78(s, IH), 7.36-7.60(m, 3H), 7.67 and 8.34(ss, 2H), 9.01(s, IH)
Example 88 : Syntheεis of (2R*, 3R* ) -2- (2, 4-dif luorophenyl )- 3- ( 4-methyl-l , 2 , 3-thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol- l-yl)-2-butanol
The same procedures as in Example 85 above were repeated using 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ ( 1H-1 , 2 , -triazol-l- yl)methyl]oxirane and 0.463 g (0.003 mol) of 4-methyl-l, 2 , 3- thiadiazol-5-thiol- a salt to afford the title compound. M.p. : 135 to 137 °C H-NMR(DMSO-d6, δ, ppm) 1.14(d, 3H), 2.61(s, 3H), 4.00(q, IH), 4.95(m, 2H), 6.63(s, IH) , 7.00-7.30(m, 3H), 7.72 and 8.26(ss, 2H)
Example 89 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(4-phenyl-l,2, 3-thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
The same procedures as in Example 85 above were repeated using 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.649 g (0.003 mol) of 4-phenyl-l, 2, 3- thiadiazol-5-thiol- Na salt to afford the title compound. M.p. : 96 to 98 °C H-NMR(DMSO-d6, δ, ppm) 1.19(d, 3H), 4.10(m, IH), 4.82(m, 2H), 6.73(8, IH), 7.05-7.50(m, 6H), 7.74 and 8.27(ss, 2H), 7.90(s, 2H)
Example 90 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[4-(2,4-difluorophenyl)-1,2, 3-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol oxalate
The same procedures as in Example 85 above were repeated using 0.502 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.753 g (0.003 mol) of 4-(2,4- difluorophenyl)-1,2,3-thiadiazol-5-thiol-Na εalt, and thereto was added 0.19 g (0.002 mol) of oxalic acid in the presence of ethyl acetate/n-hexane to afford the title compound.
M.p. : 111 to 113 °C
1H-NMR(DMSO-d6, δ, ppm) 1.34(d, 3H), 4.05(q, IH), 4.76(s,
2H), 6.65(ε, IH), 7.00-7.80(m, 6H) , 7.73 and 8.25(sε, 2H)
Example 91 : Synthesis of (2R*, 3R*)-2-(4-fluorophenyl)-3- (l,2,3-thiadiazol-5-yl)thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol oxalate
The same procedures as in Example 90 above were repeated using 0.467 g (0.002 mol) of (2R*, 3S*)-2-(4- f-luorophenyl)-3-methyl-2-[ (lH-l,2,4-triazol-l- yl)methyl]oxirane and 0.463 g (0.003 mol) of 1,2,3- thiadiazol-5-thiol-Na salt to afford the title compound. M.p. : 138 to 140 °C H-NMR(DMSO-d6, δ, ppm) 1.80(d, 3H), 4.00(q, IH), 4.83(dd, 2H), 6.30(s, IH), 7.10-7.30(m, 4H), 7.85 and 8.16(ss, 2H), 8.89(s, IH)
Example 92 : Syntheεis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(N-morpholinyl)-1,2,5-thiadiazol-4-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
A mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-mercapto-l-(lH-l,2,4-triazol-l-yl)-2- butanol, 0.617 g (0.003 mol) of 4-chloro-3-(N-morpholinyl)- 1,2,5-thiadiazole and 0.072 g (0.003 mol) of NaH in 6 ml of dimethoxyethane waε εtirred at 25 °C for 1 hour. The reaction mixture waε diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography and recrystallized from isopropyl ether to afford the title compound. M.p. : 155 to 158 °C
1H-NMR(CDC13, δ, ppm) 1.25(d, 3H), 3.45(m, 4H), 3.87(m, 4H), 4.75(q, IH), 5.00(dd, 2H), 5.40(ε, IH), 6.80-7.40(m, 3H), 7.80(8, 2H)
Example 93 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)-
3-[3-(N-thiomorpholinyl)-1,2,5-thiadiazol-4-yl]thio-1-( 1H-
1,2,4-triazol-l-yl)-2-butanol
The same procedureε as in Example 92 above were repeated using a mixture of 0.571 g (0.002 mol) of (2R*,
3R*)-2-(2, -difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-
1-yl)-2-butanol, 0.665 g (0.003 mol) of 4-chloro-3-(N- thiomorpho-linyl)-l,2,5-thiadiazole and 0.072 g (0.003 mol) of NaH in 6 ml of dimethoxyethane to afford the title compound.
M.p. : 133 to 135 °C H-NMR(CDC13, δ, ppm) 1.25(d, 3H) , 3.81(m, 4H), 3.71(m, 4H), 4.70(m, IH), 4.95(dd, 2H), 5.39(s, IH), 6.75-7.35(m, 3H),
7.77(ε, 2H)
Example 94 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-[3-(piperidin-l-yl)-l,2,5-thiadiazol-4-yl]thio-l-( 1H- l,2,4-triazol-l-yl)-2-butanol- HC1
The same procedures as in Example 92 above were repeated using a mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol- l-yl)-2-butanol, 0.611 g (0.003 mol) of 4-chloro-3- (piperidin-l-yl)-l,2,5-thiadiazole and 0.162 g (0.003 mol) of MeONa in 6 ml of methanol, and, thereafter, the compound thus obtained was recrystallized from ethyl ether by the addition of 5 ml of HCl-saturated ethyl ether to afford the title compound.
M.p. : 70 to 73 °C
1H-NMR(CDC13, δ, ppm) 1.25(d, 3H), 1.65(m, 6H) , 3.40(m, 2H),
3.50(dd, 2H), 4.70(dd, IH) , 5.00(dd, 2H), 5.50(s, IH), 6.80- 7 . 40 ( m, 3H ) , 7 . 77 and 7 . 82 ( sε , 2H )
Example 95 : Syntheεiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- [ 3- (pyrrolidin-1-yl)-1, 2 ,5-thiadiazol-4-yl ]thio-1-( 1H- l,2,4-triazol-l-yl)-2-butanol
The εame procedures as in Example 92 above were repeated using a mixture of 0.571 g (0.002 mol) of (2R*, 3R*)-2-(2,4-difluorophenyl)-3-mercapto-l-( 1H-1,2,4-triazol- l-yl)-2-butanol, 0.569 g (0.003 mol) of 4-chloro-3- (pyrrolidin-l-yl)-l,2,5-thiadiazole and 0.072 g (0.003 mol) of NaH in 6 ml of acetonitrile to afford the title compound. M.p. : 139 to 141 °C 1H-NMR(CDC13, δ, ppm) 1.25(d, 3H) , 1.99(m, 4H), 3.75(m, 4H), 4.65(dd, IH), 5.00(dd, 2H), 5.30(s, IH), 6.75-7.40(m, 3H), 7.77 and 7.82(ss, 2H)
Example 96 : Synthesis of (2R, 3R)-2-(2,4-difluorophenyl)-3- [ 3- (N-thiomorpholinyl)-1,2, 5-thiadiazol-4-yl ]thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
The same procedures as in Example 92 above were repeated using a mixture of 0.571 g (0.002 mol) of (2R, 3R)- 2-(2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)- 2-butanol, 0.665 g (0.003 mol) of 4-chloro-3-(N- thiomorpholinyl)-l,2,5-thiadiazole and 0.162 g (0.003 mol) of MeONa in 6 ml of methanol to afford the title compound. M.p. : 83 to 86 °C 1H-NMR(CDC13, δ, ppm) 1.27(d, 3H), 2.83(m, 4H) , 3.73(m, 4H), 4.73(q, IH) , 5.00(dd, 2H) , 5.41(s, IH), 6.70-7.50(m, 3H), 7.81 and 7.84(ss, 2H)
Example 97 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(1,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)- 2-butanol
To a suspension of 0.50 g (0.00175 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.59 g (0.0035 mol) of 3-chloro-l, 2- benzoisothiazole in 4 ml of acetonitrile waε added dropwiεe 1 ml of triethylamine at room temperature. The reεulting mixture was stirred for 1 hour and evaporated to obtain a concentrate, which was diluted with 100 ml of ethyl acetate, and washed with 5% sodium hydroxide aqueous solution (30 ml x 2) and then saline (30 ml x 1). The organic layer was dried over anhydrous magnesium sulfate and evaporated under reduced pressure to give a residue, which was purified by silica gel column chromatography to afford the title compound.
M.p. : 133 to 135 °C H-NMR(DMSO-d6, δ, ppm) 1.13(d, 3H), 3.71(q, IH), 4.81(dd, 2H), 6.40(s, IH), 6.85-8.05(m, 7H), 7.65 and 8.25(ss, 2H)
Example 98 : Synthesiε of (2R, 3R)-2-(2,4-difluorophenyl)-3- (1,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol
To a suεpension of 0.50 g (0.00175 mol) of (2R, 3R)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl) -2- butanol and 0.36 g (0.0021 mol) of 3-chloro-l,2- benzoisothiazole in 6 ml of acetonitrile was added dropwise 1 ml of triethylamine at 3 ± 2 °C. The resultant was processed aε in Example 97 above to afford the title compound.
M.p. : 128 to 130 °C H-NMR(CDC13, δ, ppm) 1.18(d, 3H), 3.58(q, IH), 4.90-5.10(m, 3H), 6.66-7.95( , 7H), 7.84 and 8.50(88, 2H) To a solution of 0.42 g (0.001 mol) of the title compound in 10 ml of ethyl acetate was added 0.11 g (0.0012 mol) of oxalic acid, and the resulting mixture was heated to diεεolve completely. To the resulting solution was added dropwise n-hexane to afford an oxalate of the title compound.
M.p. : 82 to 85 °C (oxalate)
To a solution of 0.42 g (0.001 mol) of the title compound in 10 ml of ethyl ether was added 10 ml of HC1- saturated ethyl ether to afford a hydrochloride of the title compound.
M.p. : 87 to 90 °C (HC1)
Example 99 : Synthesis of (2R*, 3R*)-2-(4-chlorophenyl)-3- (1,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol oxalate
To a suspension of 0.60 g (0.0021 mol) of (2R*, 3R*)-2- (4-chlorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.36 g (0.0021 mol) of 3-chloro-l,2- benzoisothiazole in 6 ml of acetonitrile was added slowly dropwise 1 ml of triethylamine at 3 ± 2 °C. The resultant was stirred for 20 minutes, and procesεed as in Example 97 above. The compound thus obtained was dissolved in ethyl acetate, and to the resulting solution was added 0.22 g
(0.0024 mol) of oxalic acid and the reεultant was heated to dissolve completely. To the resulting solution was added dropwise n-hexane to afford the title compound. M.p. : 80 to 83 °C
1H-NMR(DMSO-d6, δ, ppm) 1.10(d, 3H), 3.70(q, IH), 4.80(dd, 2H), 6.10(s, IH), 7.32-7.90(m, 8H), 7.76 and 8.17(ss, 2H)
Example 100 : Synthesiε of (2R*, 3R*)-2-(4-fluorophenyl)-3- (1,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol oxalate
To a εuspenεion of 0.50 g (0.00187 mol) of (2R*, 3R*)-2- (4-fluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.32 g (0.00187 mol) of 3-chloro-l,2- benzoisothiazole in 6 ml of acetonitrile was added slowly dropwise 0.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 20 minutes, and processed as in Example 97 above. The obtained compound waε diεεolved in ethyl acetate, and to the reεulting εolution was added 0.22 g (0.0024 mol) of oxalic acid and heated to dissolve completely. To the resulting solution was added ethyl ether to afford the title compound. M.p. : 138 to 140 °C
1H-NMR(DMSO-d6, δ, ppm) 1.14(d, 3H), 3.65(m, IH), 4.85(dd,
2H), 6.10(s, IH), 7.10-7.91(m, 8H), 7.80 and 8.19(ss, 2H)
Example 101 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- (5-chloro-l , 2-benzoisothiazol-3-yl)thio-1- ( 1H-1, 2 , 4- triazol-1-yl)-2-butanol
To a suspension of 0.70 g (0.00245 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl) -2- butanol and 0.82 g (0.0040 mol) of 3,5-dichloro-l,2- benzoisothiazole in 10 ml of acetonitrile was added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred for 1 hour and processed as in Example 97 above to afford the title compound. M.p. : 154 to 156 °C H-NMR(CDC13, δ, ppm) 1.15(d, 3H), 3.56(q, IH), 4.97(dd, 2H), 5.21(s, IH), 6.65-7.78(m, 6H), 7.79 and 7.81(sε, 2H)
Example 102 : Synthesis of (2R*, 3R*)-2-(4-chlorophenyl)-3- (5-chloro-l,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4-triazol- l-yl)-2-butanol
To a suεpension of 0.50 g (0.00176 mol) of (2R*, 3R*)-2- (4-chlorophenyl)-3-mercapto-l-( 1H-1,2,4-triazol-l-yl )-2- butanol and 0.51 g (0.0025 mol) of 3,5-dichloro-l,2- benzoisothiazole in 6 ml of acetonitrile was added slowly dropwise 1 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 30 minutes and procesεed as in Example 97 above to afford the title compound.
M.p. : 105 to 107 °C H-NMR(DMSO-d6, δ, ppm) 1.15(d, 3H), 3.68(q, IH), 4.83(dd, 2H), 6.13(s, IH), 7.33-8.10(m, 7H), 7.80 and 8.19(ss, 2H)
Example 103 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(5, 6-dimethoxy-l,2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol To a suspension of 0.60 g (0.00210 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.69 g (0.003 mol) of 3-chloro-5,6-dimethoxy- 1,2-benzoisothiazole in 10 ml of acetonitrile waε added εlowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant waε εtirred at room temperature for 30 minuteε and procesεed aε in Example 97 above to afford the title compound. M.p. : 157 to 160 °C 1H-NMR(CDC13, δ, ppm) 1.15(d, 3H) , 3.62(q, IH), 3.92 and 3.99(sε, 6H), 4.95(s, 2H) , 6.65-7.36(m, 5H), 7.78(ss, 2H)
Example 104 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3- (5-methy1-1, 2-benzoisothiazol-3-yl)thio-1-( 1H-1, 2,4- triazol-l-yl)-2-butanol
To a suspension of 0.80 g (0.0028 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.64 g (0.0035 mol) of 3-chloro-5-methyl-l,2- benzoisothiazole in 10 ml of acetonitrile was added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 30 minutes and processed as in Example 97 above to afford the title compound. M.p. : 150 to 153 °C
1H-NMR(CDC13, δ, ppm) 1.19(d, 3H), 2.44(s, 3H), 3.62(q, IH), 5.00(ε, 2H), 5.10(s, IH), 6.65-7.90(m+s, 8H)
Example 105 : Synthesiε of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(7-chloro-l, 2-benzoisothiazol-3-yl)thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol
To a suspension of 0.70 g (0.00245 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.82 g (0.004 mol) of 3,7-dichloro-l,2- benzoisothiazole in 10 ml of acetonitrile was added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 18 hourε and processed as in Example 97 above to afford the title compound. M.p. : 126 to 128 °C
1H-NMR(CDC13, δ, ppm) 1.04(d, 3H), 3.48(q, IH), 4.75-5.10(m, 3H), 6.55-7.85(m, 6H), 7.67(ε, 2H)
Example 106 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(thieno[3,4-d]isothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
To a solution of 1.0 g (0.0035 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 1.23 g (0.007 mol) of 3-chlorothieno[ 3,4- d]isothiazole in 15 ml of acetonitrile was added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 1 hour and procesεed aε in Example 97 above to afford the title compound. M.p. : 82 to 84 °C 1H-NMR(CDC13, δ, ppm) 1.13(d, 3H) , 3.64(q, IH), 4.88(ε, 2H), 5.05(s, IH), 6.60-7.40(m, 3H), 7.64 and 8.04(ss, 2H), 7.77(s, 2H)
Example 107 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(l,2-benzoisothiazol-l, l-dioxo-3-yl )thio-1- ( 1H-1, 2, 4- triazol-1-yl)-2-butanol
To a solution of 0.70 g (0.00245 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.99 g (0.0049 mol) of 3-chloro-l,2- benzoisothiazol-1, 1-dioxide in 10 ml of acetonitrile was added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The reεultant waε εtirred at room temperature for 3 hours and processed as in Example 97 above to afford the title compound. M.p. : 213 to 217 °C
1H-NMR(DMSO-d6, δ, ppm) 1.27(d, 3H), 4.81(s, 2H), 4.91(s, IH), 6.80(s, IH), 6.90-8.21(m, 7H) , 7.67 and 8.28(ss, 2H) -Example 108 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(thieno[ 3,4-d]isothiazol-1, l-dioxo-3-yl)thio-1-(1H-1,2,4- triazol-l-yl)-2-butanol
A solution of 0.50 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl ) -3-methy1-2- [ (lH-l,2,4-triazol-l-yl) methyl]oxirane, 0.57 g (0.003 mol) of 3-mercapto-thieno[ 3,4- d]iεothiazol-l, 1-dioxide and 0.42 g (0.004 mol) of lithium perchlorate in 6 ml of acetonitrile waε heated to reflux at 120 °C for 16 hours with εtirring, and proceεsed aε in Example 97 above to afford the title compound. M.p. : 149 to 151 °C
1H-NMR(CDC13, δ, ppm) 1.27(d, 3H) , 4.94(dd+q, 3H), 5.54(s, IH), 6.67-7.40(m, 3H), 7.62-7.88(m, 4H)
Example 109 : Synthesiε of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-(2, l-benzoisothiazol-3-yl)thio-1- ( 1H- 1,2,4-triazol-l-yl)-2-butanol
<method 1>
To a solution of 0.57 g (0.002 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.47 g (0.0022 mol) of 3-bromo-2,l- benzoisothiazole in 6 ml of methanol was added 0.27 g (0.005 mol) of sodium methoxide. The resultant was heated to reflux for 10 minutes with stirring, and processed as in Example 97 above to afford the title compound. M.p. : 91 to 93 °C H-NMR(DMSO-d6, δ, ppm) 1.19(d, 3H), 4.10(q, IH) , 4.95 and 5.06(dd, 2H), 6.65(s, IH) , 7.00-7.92(m, 7H), 7.74 and 8.34(sε, 2H)
<method 2>
A solution of 0.50 g (0.002 mol) of (2R*, 3S*)-2-(2,4- difluorophenyl) -3-methyl-2- [ (lH-l,2,4-triazol-l-yl) methyl]oxirane, 0.50 g (0.003 mol) of 3-mercapto-2, 1- benzoisothiazole and 0.42 g (0.004 mol) of lithium perchlorate in 6 ml of acetonitrile was heated to reflux at 100 °C for 15 hours with stirring, and proceεsed aε in Example 97 above to afford the title compound.
Example 110 : Syntheεis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(5-nitro-2,l-benzoiεothiazol-3-yl)thio-l-(lH-l,2,4- triazol-1-yl)-2-butanol
To a εolution of 0.57 g (0.002 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl) -2- butanol and 0.57 g (0.0022 mol) of 3-bromo-5-nitro-2,1- benzoiεothiazole in 6 ml of methanol was added 0.27 g (0.005 mol) of sodium methoxide. The resultant was stirred at room temperature for 30 minutes, and processed as in Example 97 above to afford the title compound. M.p. : 142 to 144 °C
1H-NMR(DMSO-d6, δ, ppm) 1.28(d, 3H), 4.40(m, IH), 4.94(m, 2H), 6.83(8, IH), 7.00-8.31(m, 6H), 7.77 and 8.74(εs, 2H)
Example 111 : Synthesis of (2R*, 3R*)-2-(2,4-difluorophenyl)- 3-(isothiazolo[3,4-b]pyridin-3-yl)thio-1-(1H-1,2,4-triazol- 1-yl)-2-butanol
To a solution of 0.57 g (0.002 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.43 g (0.002 mol) of 3-bromoisothiazolo[3,4- b]pyridine in 10 ml of acetonitrile waε added slowly dropwise 1.5 ml of triethylamine with cooling at an ice bath. The resultant was stirred for 15 minutes, and processed as in Example 97 above to afford the title compound.
M.p. : 148 to 150 °C 1H-NMR(CDC13, δ, ppm) 1.26(d, 3H), 3.91(q, IH) , 5.05 and 5.18(dd, 2H), 5.55(s, IH), 6.73-8.96(m, 7H), 7.85(ε, 2H)
Example 112 : Synthesis of (2R*, 3R*)-2-(2,4- difluorophenyl)-3-(1,2-benzoisoxazol-3-yl)thio-1-(1H-1,2,4- triazol-l-yl ) -2-butanol oxalate
To a solution of 0.60 g (0.0023 mol) of (2R*, 3R*)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.70 g (0.00464 mol) of 3-chloro-l,2- benzoisoxazole in 10 ml of methanol was added 0.1 g of potasεium iodide and 0.27 g (0.005 mol) of εodium methoxide. The resultant was heated to reflux for 15 hours with stirring, and processed as in Example 97 above to afford the title compound.
M.p. : 80 to 82 °C
1H-NMR(DMSO-d6, δ, ppm) 1.25(d, 3H), 4.86(m, 3H), 6.60(s,
IH), 7.00-7.50(m, 7H), 7.65 and 8.29(ss, 2H)
Example 113 : Synthesiε of (2R, 3R)-2-(2,4-difluorophenyl)- 3-(thieno[3,4-d]isothiazol-3-yl)thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol
To a solution of 0.5 g (0.00175 mol) of (2R, 3R)-2- (2,4-difluorophenyl)-3-mercapto-l-(1H-1,2,4-triazol-l-yl)-2- butanol and 0.6 g (0.0035 mol) of 3-chlorothieno[3,4- d]isothiazole in 15 ml of acetonitrile was added slowly dropwise 1 ml of triethylamine with cooling at an ice bath. The resultant was stirred at room temperature for 1 hour, and processed as in Example 97 above to afford the title compound.
M.p. : 129 to 131 °C H-NMR(CDC13, δ, ppm) 1.13(d, 3H), 3.64(q, IH) , 4.88(s, 2H), 5.05(8, IH), 6.60-7.40(m, 3H), 7.64 and 8.04(dd, 2H), 7.77(s, 2H)
Activity Test
The compounds of formula (I) of the present invention were tested to measure their antifungal activities as follows.
1. systemic candidosiε in mice Male ICR mice (22 to 25 g) were divided into 48 groups, each consisting of ten mice. The first was a control group employing no teεt compound, the second was a comparative group employing Fluconazole, a commercially available triazolic antifungal agent, and the 3rd to 48th were employed the compounds of the present invention. Candida albicans B02630 waε cultured in SDA medium for 24 hours, and then suεpended in a sterilized saline in a concentration of 4.0 x 107 CFU/ml. All the test animals were infected by injecting 0.2 ml of the fungi εuεpension into tail vein. Immediately after the injection, Fluconazole and the inventive compoundε disεolved in polyethylene glycol 200 were adminiεtered orally in an amount of 2 mg/kg into the second group and the 3rd-48th group, respectively. The test compounds were administered three times at an interval of 24 hours. The number of the mice survived was counted at 24 hour interval and the results are shown in Table 5.
Table 5
2. Effectiveneεε againεt fungal infections
A. ED50 against Candida albicanε
Male ICR mice (22 to 25 g) of 36 groupε, each group consisting of eight mice, were infected by Candida albicans in accordance with the same procedures aε deεcribed previouεly. Immediately after the infection, the inventive compound (prepared in Example 5 of the preεent invention) disεolved in polyethylene glycol 200 was administered orally in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg into the 2nd-6th group five ti eε at an interval of 24 hours. No compound was administered into the first group. The inventive compounds prepared in Example 47, 72, 73, 93, 97 and 98 were also administered orally into the remaining 7th- 36th groups in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg. The number of the mice survived was counted at 24 hour interval.
Separately, the above procedures were repeated using Fluconazole as a comparative compound. After 14 days, the ED50 value was calculated from the number of the mice survived in accordance with Litchfield-Wilcoxon method, and the results are shown in Table 6.
B. ED50 against by cryptococcus neoformans
Male ICR mice (22 to 25 g) were divided into 36 groupε, each group conεisting of eight mice. Cryptococcus neoformans IFM 40092 was cultured in SDA medium for 24 hours, and then suspended in a sterilized εaline in a concentration of 2.0 x 108 CFU/ml. To each group cyclophosphamide as a immunosuppressive agent was administered intraperitoneally in an amount of 2 mg/mouse. 24 hourε after the administration, each group was infected by injecting into tail vein 0.2 ml of the fungi suspension. 2 hours after the infection, the inventive compounds prepared in Example 5, 47, 72, 73, 93, 97 and 98 of the present invention were administered into the the test animals in each amount of 20, 10, 5, 2.5 and 1.25 mg/kg as described previously The ED50 values measured are shown in Table 6.
EDS0 against Asperσillus fumiqatus
Male ICR mice (22 to 25 g) were divided into 36 groups, each group consisting of eight mice. To each group cyclophosphamide (immunoεuppresεive agent) was administered intraperitoneally in an amount of 2 mg/mouse. 24 hours after the administration, each group was infected by injecting into tail vein 0.2 ml of a suspension of Asperqillus fumiσatus 3319119 spore (2.0 x 106 CFU/ml in a sterilized saline) . 48 hours after the infection, the inventive compounds prepared in Example 5, 47, 72, 73, 93, 97 and 98 of the present invention were administered into the the test animals in each amount of 100, 50, 25, 12.5 and 6.25 mg/kg as described previously. The ED50 values measured are shown in Table 6.
Table 6
As shown above, the compounds of formula(I) and their pharmacologically acceptable salts of the present invention have a potent antifungal activity against variouε fungi, e.g., Candida albicanε, Cryptococcus neoformans, and Asperqillus fumigatuε and, therefore, can be used for the treatment of fungal infections in mammals including human beings.
While the invention has been described in connection with the above specific embodiments, it εhould be recognized that various modifications and changes may be made to the present invention and also fall within the εcope of the invention as defined by the claims that follow.

Claims

What is claimed is
1. A triazole compound of the following formula(I) and the pharmacologically acceptable salts thereof:
wherein:
X and Y are each independently a hydrogen or halogen; and R is a group selected from the formulae consisting of (I-a), (I-b), (I-c), (I-d), (I-e), (I-f), (I-g), (I-h), (I-i) and (I-j)
(I-a) (I-b) (I-c)
wherein Z is a nitrogen or carbon; R1 represents '1-4 alkoxy, -1-4 alkoxymethyl, '1-4 alkylthio, '1-4 alkylthio ethyl, amino, C._4 alkyla ino group which may form a ring with a nitrogen atom, or an optionally substituted C._ alkyl, styryl, phenyl or heteroaryl group; R2 represents a hydrogen or C,_3 alkyl, phenyl, substituted phenyl, morpholinyl, pyrolidinyl, thiomorpholinyl or piperidinyl group; and R3 represents a hydrogen or halogen or a C._3 alkyl, C,_3 alkoxy or nitro group.
2. The compound of claim 1 wherein R is a group of the following formula (I-a):
N—R Z (I-a) wherein R.. is the same as defined in claim 1.
3. The compound of claim 2 which is selected from the group consisting of:
(2R*, 3R*) -2- (2, 4-difluorophenyl) -3- (3-t-butyl-l, 2,4- thiadiazol-5-y1)thio-1-(1H-1,2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3- (3-methylthio-l , 2,4- thiadiazol-5-y1)thio-1-(1H-1,2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2- (2,4-difluorophenyl)-3-(3-cyclopropyl-l, 2,4- thiadiazol-5-yl)thio-l-( 1H-1,2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2, -difluorophenyl)-3-( 3-isopropyl-l, 2,4- thiadiazol-5-yl)thio-l-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl)-3- ( 3-methoxy-1 , 2,4- thiadiazol-5-yl)thio-l-(1H-1, 2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2 , 4-difluorophenyl)-3-(3-chloromethyl-l,2, 4- thiadiazol-5-yl)thio-1-(1H-1, 2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl )-3-(3-dimethylamino-l, 2,4- thiadiazol-5-yl )thio-1-( 1H-1, 2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(pyrrolidin-l-yl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol; (2R*, 3R*)-2-(2,4-dif luorophenyl) -3- (3-amino-l, 2,4- thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2 -butanol ;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- ( 3-ethoxy-l , 2,4- thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- ( 3-methacryl-l , 2,4- t'hiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol;
(2R*, 3R*) -2- (2, 4-dif luorophenyl) -3- (3-methylthiomethyl-
1,2, 4-thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- ( 3 -ethyl- 1 , 2,4- thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 1-chloroethyl ) -1 , 2 , 4- thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol;
(2R*, 3R*) -2- (2, 4-dif luorophenyl) -3- (3-methoxymethyl-l, 2,4- thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2 -butanol ;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 4-methoxystyryl ) - l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
( 2R*,3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 3 , 5-dimethylpyrazol- 1-yl ) -1 , 2 , 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) - 2 -butanol;
(2R*, 3R* )-2- (2, 4-dif luorophenyl)- 3- (3-croty 1-1, 2, 4- thiadiazol-5-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2 -butanol ;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 4-f luorostyryl ) ■ 1,2, 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2* butanol;
(2R*, 3R*) -2- (2, 4-dif luorophenyl) -3- [3- (4- (2, 2, 3,3* tetrafluoropropoxy)styryl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(3-fluoromethyl-1,2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(3-phenoxymethyl-l,2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(2-fluorophenyl)- 1, 2,4-thiadiazol-5-yl ]thio-1- ( 1H-1 , 2 , 4-triazol-l-yl )-2- butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(2, 6-difluorophenyl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-fluorophenyl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[ 3-(2-pyridyl)-1, 2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(2-chlorophenyl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2- (2 , 4-difluorophenyl ) -3- ( 3-phenyl-1 , 2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(3-pyridyl)-1,2, 4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-pyridyl)-1,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl)-3-[4-( l- (N- hydroxyiminoethyl)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(4-chlorophenyl)-3-[3-(3,5-difluorophenyl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2,4-dichlorophenyl)-3-[3-(4-pyridyl)-1,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-chlorophenyl)- 1,2,4-thiadiazol-5-yl ]thio-1- ( 1H-1, 2 , 4-triazol-l-yl ) -2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(3-fluorophenyl)- 1,2, 4-thiadiazol-5-yl ]thio-1- ( 1H-1 , 2 , 4-triazol-1-yl ) -2- butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(3,4-difluorophenyl)- 1,2,4-thiadi"azol-5-yl ]thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(2,6-dichlorophenyl)- l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
( 2R*, 3R*) -2- ( 2 , 4-difluorophenyl ) -3- [ 3- ( 3- trifluoromethylphenyl)-1,2,4-thiadiazol-5-yl]thio-1-( 1H- 1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[ 3-(3-chlorophenyl)- 1,2, 4-thiadiazol-5-yl ]thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-(lH-imidazol-l- yl)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol; (2R*, 3R*)-2-(2,4-difluorophenyl)-3-[ 3-(2-pyrazinyl)-1, 2, 4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*) -2-(2, 4-difluorophenyl ) -3- [ 3- ( 2-chloro-6- fluorophenyl )-l, 2 , 4-thiadiazol-5-yl ]thio-l-(lH-l,2,4- triazol-1-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-bromophenyl)-1,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(4-(lH-l,2,4-triazol- 1-yl)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol- 1-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-azidophenyl)-1,2,4- thiadiazol-5-yl]thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2- (2 , 4-difluorophenyl ) -3- [ 3- ( 3 , 5- bistrifluoromethylphenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*) -2- (2, 4-difluorophenyl)-3- (3-styryl-l, 2,4- thiadiazol-5-yl)thio-1-(1H-1 , ,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-morpholin-l- yl)phenyl-l,2,4-thiadiazol-5-yl]thio-l-(1H-1,2,4-triazol-l- y1)-2-butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(3-trifluoromethyl-4- acetylamino)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4- triazol-1-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-(1, 3,4-oxadiazol-2- yl)phenyl)-1,2,4-thiadiazol-5-yl]thio-l-(1H-1,2,4-triazol-l- yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[ 3-(4-( 1, 3-dioxolan-2- ylJphenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l- yl ) -2-butanol ;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-cyanophenyl)-1,2,4- thiadiazol-5-yl]thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(thiophen-2-yl)-1,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-nitrophenyl)-1,2,4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[ 3-(pyrimidin-5-yl)- 1,2,4-thiadiazol-5-yl ]thio-1- ( 1H-1, 2 , 4-triazol-1-yl ) -2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-biphenyl)-1,2, 4- thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
( 2R*, 3R*)-2- (2 , 4-difluorophenyl )-3-[3-(4-(2, 2,3,3- tetrafluoropropoxy)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H- 1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(4-(4-pyridon-l- yl)phenyl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2,4-triazol-l- yl)-2-butanol;
(2R*,3R*) -2- ( 2,4-difluorophenyl)-3-[3-(4-methylpyrimidin-2- yl)-1,2,4-thiadiazol-5-yl]thio-1-(1H-1,2, -triazol-l-yl)-2- butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(pyridin-N-oxo-4-yl)- 1,2,4-thiadiazol-5-yl ]thio-1-( 1H-1 , 2 , 4-triazol-1-yl ) -2- butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[3-(4-methylthiophenyl)- 1,2, 4-thiadiazol-5-yl ]thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol; ( 2R* , 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 4- methanesulfonylphenyl)-l , 2 , 4-thiadiazol-5-yl ]thio-l- ( 1H- 1,2, 4-triazol-l-yl ) -2-butanol;
(2R*, 3R*) -2- (2, -dif luorophenyl) -3- [3- (3-nitrophenyl) -1,2,4- thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2 -butanol;
( 2R*,3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 2 , 5-dif luorophenyl ) - l,2,4-thiadiazol-5-yl]thio-l- ( 1H-1,2, 4-triazol-l-yl ) -2- butanol;
(• 2 R* , 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- ( 4- dimethylaminophenyl ) -1 , 2 , 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4- triazol-1-yl) -2 -butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(lH-l,2,4-triazol-l- yl )methyl-l , 2 , 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l- yl)-2-butanol;
(2R*, 3R*)-2- (2, 4-dif luorophenyl )-3-[ 3- (4-methoxystyryl )- 1,2, 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol;
( 3R*) -2- ( 2 , -dif luorophenyl ) -3- [ 3- ( 3-pyrrol-l-yl )phenyl- 1,2, 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2- butanol;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- (pyridazin-3-yl ) - l,2,4-thiadiazol-5-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*) -2- (2, 4-dif luorophenyl) -3- [3- (l-chloro-2 - methoxyethyl) -1,2, 4-thiadiazol-5-yl ] thio-1- ( 1H-1 , 2 , 4- triazol-1-yl ) -2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(3-methoxymethyl-l,2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol; (2R, 3R) -2- (2, 4-difluorophenyl) -3- ( 3-styryl-l, 2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R, 3R)-2-(2, 4-difluorophenyl) -3- (3-methoxy-1,2,4- thiadiazol-5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*,3R*)-2-(4-chlorophenyl)-3-(3-methoxy-l,2,4-thiadiazol- 5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
('2R*,3R*)-2-(4-fluorophenyl)-3-(3-methoxy-l,2,4-thiadiazol- 5-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(4-fluorophenyl)-3-(3-styryl-l,2,4-thiadiazol-5- yl)thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[4-(2, 6-difluorophenyl)- thiazol-2-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[4-(2,4-dichlorophenyl)- thiazol-2-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[4-(4-chlorophenyl)- thiazol-2-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
('2R*, 3R*)-2-(2,4-difluorophenyl)-3-(4-ethylthiazol-2- yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
( 2R*, 3R*)-2- (2 , 4-difluorophenyl)-3- [ 4- ( 1-hydroxy-l- methylethyl)-thiazol-2-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(4-styrylthiazol-2- yl)thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*) -2-(2,4-difluorophenyl)-3-[4-(4-methoxystyryl)- thiazol-2-yl]thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol; and
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[4-(2, 3-dichlorostyryl)- thiazol-2-y1 ]thio-1-(1H-1, 2,4-triazol-1-yl)-2-butanol .
4. The compound of claim 1 wherein R is a group of formula (I-b) or (I-c) :
wherein R2 is the same as defined in claim 1.
5. The compound of claim 4 which is selected from the group consisting of:
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-( 1, 2, 3-thiadiazol-5- yl)thio-1-(1H-1, 2,4-triazol-l-yl)-2-butanol;
(2R*,3R*)-2-(4-chlorophenyl)-3-(l,2,3-thiadiazol-5-yl)thio- 1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-dichlorophenyl)-3-(l,2,3-thiadiazol-5- yl)thio-1-( 1H-1,2,4-triazol-l-yl)-2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-difluorophenyl ) -3- ( 4-methyl-1 , 2,3- thiadiazol-5-yl)thio-l-( IH-1,2,4-triazol-1-yl) -2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-difluorophenyl ) -3- (4-phenyl-l , 2,3- thiadiazol-5-yl)thio-1-( 1H-1,2,4-triazol-l-yl )-2-butanol;
(2R*,3R*)-2-(2,4-difluorophenyl)-3-[4-(2 , 4-difluorophenyl) - 1,2, 3-thiadiazol-5-yl]thio-l-( lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*,3R*)-2-(4-fluorophenyl)-3-(1,2, 3-thiadiazol-5-yl)thio- 1-( 1H-1,2, 4-triazol-l-yl)-2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- [ 3- (N-morpholinyl ) -1 , 2 , 5- thiadiazol-4-yl ] thio- l - ( 1H- 1 , 2 , 4- triazol- 1-yl ) -2 -butanol ; (2R*, 3R*)-2- (2 , 4-difluorophenyl )-3-[ 3-(N-thiomorpholinyl) l,2,5-thiadiazol-4-yl]thio-l-( lH-1,2, 4-triazol-l-yl ) -2 butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(piperidin-l-yl) l,2,5-thiadiazol-4-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2 butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-[3-(pyrrolidin-1-yl) l,2,5-thiadiazol-4-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2 butanol; and
(2R, 3R)-2-(2,4-difluorophenyl)-3-[3-(N-thiomorpholinyl) l,2,5-thiadiazol-4-yl]thio-l-(lH-l,2,4-triazol-l-yl)-2 butanol.
6. The compound of claim 1 wherein R is a group selecte from the formulae consisting of (I-d), (I-e), (I-f), (I-g) (I-h), (I-i) and (I-j):
wherein R3 is the same as defined in claim 1.
7. The compound of claim 6 which is selected from th group consisting of: ( 2R*, 3R*) -2- ( 2 , 4-dif luorophenyl ) -3- ( 1 , 2-benzoisothiazol-3- yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol;
( 2R, 3R) -2- ( 2 , 4-dif luorophenyl ) -3- ( 1 , 2-benzoisothiazol-3-yl ) thio-l-(lH-l,2,4-triazol-l-yl)-2-butanol;
( 2R*, 3R*) -2- ( 4-chlorophenyl ) -3- ( 1 , 2-benzoisothiazol-3-yl ) thio-1- ( 1H-1 , 2 , 4-triazol-l-yl ) -2-butanol ;
(2R*, 3R*)-2-(4-fluorophenyl)-3-(l,2-benzoiεothiazol-3-yl) thio-l-(lH-l,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2- (2, 4-difluorophenyl) -3- (5-chloro-l, 2- benzoiεothiazol-3-yl)thio-l-(lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(4-chlorophenyl)-3-(5-chloro-l,2- benzoisothiazol-3-yl)thio-l-( 1H-1, 2, 4-triazol-1-yl ) -2- butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(5, 6-dimethoxy-l, 2- benzoisothiazol-3-yl )thio-l- (lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl )-3- (5-methyl-l, 2- benzoisothiazol-3-yl )thio-l- (lH-l,2,4-triazol-l-yl)-2- butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl) -3- (7-chloro-1, 2- benzoisothiazol-3-yl )thio-l- (lH-l,2,4-triazol-l-yl)-2- butanol;
(-2R*, 3R*)-2-(2,4-difluorophenyl)-3-(thieno[3,4-d]isothiazol- 3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2,4-difluorophenyl)-3-(1,2-benzoisothiazol-l, 1- dioxo-3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol; (2R*, 3R*) -2-(2,4-difluorophenyl)-3-(thieno[ 3,4-d]isothiazol- 1, l-dioxo-3-yl)thio-1-( 1H-1, 2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*) -2-(2,4-difluorophenyl)-3-(2, l-benzoisothiazol-3- yl)thio-1-(1H-1,2, 4-triazol-l-yl)-2-butanol;
( 2R*, 3R*) -2- ( 2 , 4-difluorophenyl )-3-(5-nitro-2, l- benzoisothiazol-3-yl )thio-l-( 1H-1 , 2 , 4-triazol-1-yl )-2- butanol;
(2R*, 3R*) -2-(2, 4-difluorophenyl ) -3- ( isothiazolo[ 3,4- b]pyridin-3-yl)thio-1-( 1H-1, 2, 4-triazol-l-yl)-2-butanol;
(2R*, 3R*)-2-(2, 4-difluorophenyl)-3-(1, 2-benzoisothiazol-3- yl)thio-l-(1H-1,2,4-triazol-l-yl)-2-butanol oxalate; and
(2R, 3R)-2-(2,4-difluorophenyl)-3-(thieno[3,4-d]isothiazol- 3-yl)thio-1-(1H-1,2,4-triazol-l-yl)-2-butanol .
8. A process for preparing a triazole compound of formula (I) comprising reacting a compound of formula (II) with a compound of formula (III) or its alkali metal salt in the presence of lithium perchlorate:
HS - R (Hi)
wherein: X, Y and R are the same as defined in claim 1.
9. A process for preparing a triazole compound of formula (I) comprising reacting a compound of formula (IV) with* a compound of formula (V) in the presence of a base:
L - R (V) wherein:
X, Y and R are the same as defined in claim 1; L is a halogen.
10. A pharmaceutical composition comprising a therapertically effective amount of the triazole compound defined in claim 1 as an active ingredient, and a pharmaceutically acceptable carrier or adjuvant.
EP95912490A 1994-03-12 1995-03-13 Triazole compounds and processes for the preparation thereof Ceased EP0751943A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
KR9404918 1994-03-12
KR1019940004918A KR950026875A (en) 1994-03-12 1994-03-12 Triazole derivatives and preparation method thereof
KR1019940004917A KR950026874A (en) 1994-03-12 1994-03-12 Triazole derivatives and preparation method thereof
KR9404917 1994-03-12
KR1019940012285A KR960000880A (en) 1994-06-01 1994-06-01 Triazole derivatives and preparation method thereof
KR9412285 1994-06-01
PCT/KR1995/000019 WO1995025107A1 (en) 1994-03-12 1995-03-13 Triazole compounds and processes for the preparation thereof

Publications (1)

Publication Number Publication Date
EP0751943A1 true EP0751943A1 (en) 1997-01-08

Family

ID=27349055

Family Applications (1)

Application Number Title Priority Date Filing Date
EP95912490A Ceased EP0751943A1 (en) 1994-03-12 1995-03-13 Triazole compounds and processes for the preparation thereof

Country Status (4)

Country Link
EP (1) EP0751943A1 (en)
JP (1) JPH09505083A (en)
AU (1) AU1961695A (en)
WO (1) WO1995025107A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5779598A (en) * 1997-02-04 1998-08-25 Sankyo Company Limited Triazole derivatives
WO2000027852A1 (en) * 1998-11-10 2000-05-18 Meiji Seika Kaisha, Ltd. Novel imidazo[5,1-b]thiazole derivatives and fungicides containing the same as the active ingredient
HUP0303249A3 (en) 2001-02-22 2007-03-28 Sankyo Co Water-soluble triazole fungicide compounds and pharmaceutical compositions containing them
DE10332288B4 (en) * 2003-07-16 2009-07-30 Skw Stickstoffwerke Piesteritz Gmbh Use of 1,2,4-thiadiazole-5-thio compounds and their derivatives as urease inhibitors
PL371841A1 (en) 2004-12-20 2006-06-26 ADAMED Sp.z o.o. New derivatives of 3-phenylpropionic acid
PL372332A1 (en) 2005-01-19 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
PL372356A1 (en) * 2005-01-20 2006-07-24 ADAMED Sp.z o.o. New compounds, derivatives of 3-phenylpropionic acid
JP5804811B2 (en) * 2010-07-13 2015-11-04 住友化学株式会社 Process for producing fused ring compound, and raw material compound used in the process

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK157135C (en) * 1982-04-07 1990-04-02 Pfizer METHOD OF ANALOGUE FOR THE PREPARATION OF 1,2,4-TRIAZOL COMPOUNDS OR PHARMACEUTICAL ACCEPTABLE ACID ADDITION SALTS.
US4507484A (en) * 1982-07-24 1985-03-26 Pfizer Inc. Triazole antifungal agents
IE903395A1 (en) * 1989-09-26 1991-04-10 Takeda Chemical Industries Ltd Triazole compounds, their production and use
CA2038201A1 (en) * 1990-03-15 1991-09-16 Katsumi Itoh Triazoles, their production and use
IE912990A1 (en) * 1990-08-26 1992-03-11 Sankyo Co Anti-fungal triazole derivatives, their preparation and¹uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9525107A1 *

Also Published As

Publication number Publication date
WO1995025107A1 (en) 1995-09-21
JPH09505083A (en) 1997-05-20
AU1961695A (en) 1995-10-03

Similar Documents

Publication Publication Date Title
EP0567982B1 (en) Azole compounds, their production and use
EP0783501B1 (en) pyrimidone derivatives with antifungal activity
AU777859B2 (en) N-substituted carbamoyloxyalkyl-azolium derivatives
FI119548B (en) Apolipoprotein B synthesis inhibitors
US20160256440A1 (en) Multisubstituted aromatic compounds as inhibitors of thrombin
US7189858B2 (en) N-phenyl substituted carbamoyloxyalkyl-azolium derivatives
WO2001068585A1 (en) Novel amide compounds
BG107985A (en) Substituted triazole diamine derivatives as kinase inhibitors
MXPA97002382A (en) New pyrimidone derivatives with activityantifung
AU2007206746A1 (en) Chemical compounds
AU600107B2 (en) 4-(4-(4-((2-(2,4-difluorophenyl)-2-(1h-azolylmethyl)-1,3- dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl) triazolones
EP0657449B1 (en) Azole compounds, their production and use as antifungal agents
AU714701B2 (en) Novel thiophene derivative and pharmaceutical composition thereof
EP0751943A1 (en) Triazole compounds and processes for the preparation thereof
EP0133248B1 (en) 1,2,4-triazol-1-yl-derivatives
CZ282897A3 (en) N-benzylazolium derivatives
AU740324B2 (en) New triazoles as therapeutic agents for fungal infections
HU192964B (en) Process for preparing thiatriazine derivatives and pharmaceutical compositions containing such compounds
US6784184B2 (en) 5-(arylsulfonyl)-,5-(arylsulfinyl), and 5-(arylsulfanyl)-thiazolidine-2,4-diones useful for inhibition of farnesyl-protein transferase
US4595535A (en) Diazacycloalkyl-1,2,4-triazolo[2,3-c][1,3]benzodiazepines useful as neuroleptic and/or antihistaminic agents
JPH09183769A (en) Azole compound and its use
JPH08104676A (en) Azole compound, its production and use
US20030144301A1 (en) Method of using 5-(arysulfonyl)-, 5-(arylsulfanyl)-and 5-(arylsulfanyl)thiazolidine-2,4-diones for inhibition of farnesyl-protein transferase
JPH07228574A (en) Optically active azole derivative, its production and use thereof
JPS606689A (en) Trisazolo(2,3-c)(1,3)benzodiazepines, manufacture and medicinal composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19960905

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19980113

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 19990327